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ABSTRACT 
UTILIZING GENETICALLY ENGINEERED MOUSE MODELS OF 
PANCREATIC CANCER: IDENTIFICATION OF CATHEPSIN B AS A 
THERAPEUTIC TARGET AND EVALUATING THE EFFICACY OF FARNESYL 
THIOSALICYLIC ACID 
Aarthi Gopinathan 
David A. Tuveson 
I have utilized genetically engineered mouse models of pancreatic cancer to identify a 
potential new therapeutic target, and to test the efficacy of a putative ras inhibitor. In 
the first part, I show that cathepsin B is upregulated during disease progression in the 
mouse pancreas, as is overall cathepsin activity. Loss of cathepsin B decreases 
preinvasive disease burden and imparts a significant survival benefit, with a consistent 
decrease in proliferation. In addition, lack of cathepsin B also decreases the burden of 
liver metastasis. Phospho-Erk localization appears to be affected by cathepsin B loss, 
which may account for the defect in proliferation. Cathepsin B null tumours also have 
increased active cathepsin L, which may compensate for cathepsin B in tumour 
progression and metastasis. Finally, a cysteine protease inhibitor in combination with 
gemcitabine confers a significant increase in survival in tumour-bearing mice. In the 
second part of this work, I have investigated the effect of farnesylthiosalicylic acid 
(FTS) in pancreatic tumour-bearing mice. In combination with gemcitabine, FTS 
significantly increases survival and decreases tumour kinetics and proliferation, and 
inhibits liver metastasis. Although FTS has previously been reported as a ras inhibitor, 
there is no evidence of modulation of ras activity or signaling in primary tumours 
after long-term or short-term intervention, or in liver metastases. In short, the 
therapeutic effects of FTS in this mouse model of pancreatic cancer do not appear to 
be ras-related, and the target of FTS remains to be elucidated. 
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INTRODUCTION 
Pancreatic ductal adenocarcinoma 
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with a median survival of 
< 6 months and a 5-year survival rate of < 5%. It is the fourth-leading cause of 
cancer-related deaths in the United States, with an estimated 42,000 new cases and 
35,000 deaths in 2009 (1). It is the most frequent type of pancreatic malignancy, 
accounting for >85% of cases (2).  Risk factors for PDA include chronic pancreatitis, 
diabetes, obesity, advanced age and smoking (3-8). Approximately 10% of PDAs are 
associated with familial syndromes that confer an increased  risk, corresponding with 
germline mutations that target tumour suppressors such as Brca2, Ink4a and Lkb1 and 
the DNA repair gene Mlh1 (9-11). 
Chronic pancreatitis, a fibroinflammatory disease of the pancreas that causes 
irreversible loss of exocrine and endocrine function (12), is caused by various factors 
including excessive alcohol consumption, smoking, autoimmune disorders and 
genetic mutations. Long-standing chronic pancreatitis greatly increases the risk of 
developing pancreatic cancer (13). Genes associated with pancreatitis are often linked 
to increased occurrence of PDA. Germline mutations in Prss1 which cause hereditary 
pancreatitis are associated with a 53-fold increase in PDA occurrence (14).  In addition 
mutations in the cystic fibrosis transmembrane conductance regulator and Spink1 
genes, both of which are associated with pancreatic disease, may increase the risk of 
PDA (15, 16). Pancreatitis may promote tumorigenesis due to the release of growth 
factors and cytokines and the induction of reactive oxygen species, which in-turn 
would stimulate proliferation and selection of oncogenic mutations. Indeed, up to one-
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third of patients with chronic pancreatitis carry activating mutations in the Kras 
oncogene (17).  
Contributing to the dismal diagnosis of PDA is the difficulty in detecting early 
tumours, with a large number of patients presenting with advanced and metastatic 
disease ( reviewed in 2, 18).  Only an estimated 10 - 15% of patients at first diagnosis 
possess tumours that can be resected by radical pancreatico-duodenectomy. In this 
subset of patients, disease almost always recurs and 5-year survival does not exceed 
10 – 25% (19). The majority of patients present with non-specific symptoms including 
jaundice and back pain, relating to the location of the primary tumour. Manifestations 
of more advanced disease include ascites, weight-loss, cachexia, obstruction of the 
gastric outlet and thromboembolic disease (20).   
Primary tumours are commonly located at the head of the pancreas, and infiltrate 
surrounding organs including the spleen, lymph nodes and peritoneal cavity, with 
metastasis to the liver and lungs. PDAs primarily exhibit glandular histology, 
although others such as sarcomatoid, colloid and adenosquamous are also found (21). 
Tumour heterogeneity results in multiple histologies and differentiation grades within 
a single tumour. The tumours are characterized by a dense desmoplastic reaction with 
fibroblasts and immune cells as well as deposition of an extracellular matrix 
consisting of proteins such as collagens, laminin and fibronectin among others (reviewed 
in 22,23). PDAs tend towards early dissemination, and even small primary tumours 
exhibit lymphoid, vascular and perineural invasion (24).   
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Genetics and histology of pancreatic cancer 
The genetic and histologic progression of pancreatic cancer has been analyzed from 
resected tumour specimens, giving insight into the mechanism of disease initiation 
and progression. Histologically, the model for disease progression describes 
increasing grades of preinvasive Pancreatic Intraepithelial Neoplasia (PanIN), 
characterized by a range of morphological alterations which suggest increasing grades 
of dysplasia. Normal pancreatic ducts consist of a single layer of cuboidal ductal 
epithelial cells with basally localized nuclei. The earliest preneoplasm is the 
PanIN1A, where the epithelial cells are columnar and comprised of an enlarged 
mucinous apical cytoplasm. In PanIN1Bs, the ducts start to develop papillary 
projections. PanIN2s are characterized by nuclear atypia, with nuclei losing their 
basal localization. The highest grade of preneoplasm is the PanIN3, described as 
ductal carcinoma in situ, with epithelial cells forming multiple layers and detaching 
into the lumen. This is followed by frank carcinoma, with invasion of the surrounding 
basement membrane. (25, 26).  Activating mutations in the Kras oncogene have been 
identified as the initiating event, present in >90% of tumours. Other common genetic 
events include the inactivation of the Ink4a/Arf locus, point mutations in the tumour 
suppressor Trp53, and mutations or deletions of Smad4 (18)  (Fig I.1).   
Mouse models of pancreatic cancer 
Mouse models of PDA have been described with KrasG12D as the initiating mutation 
that recapitulate the progression of the human disease, a process that is accelerated by 
the concomitant expression of a point-mutant Trp53 allele (27, 28). The KrasG12D allele 
is introduced as a conditional mutation, under the control of a floxed transcriptional  
  
 
Figure I.1 Model showing the genetic and histologic progression of pancreatic 
cancer. The progression from normal ducts to PDA involves a progression with 
varying grades of dysplasia. Normal ducts consist of a single layer of cuboidal ductal 
epithelial cells. The path to carcinoma involves various grades of preinvasive 
Pancreatic Intraepithelial Neoplasia (PanIN), encompassing altered morphology, 
nuclear atypia and carcinoma in situ, followed by invasion into the basement 
membrane to form frank PDA. The initiating genetic event is mutation of the Kras 
oncogene, which is the earliest and most frequent event. Alterations in tumour 
suppressors such as p16, p53, DPC4 and Brca2 contribute to progression.  
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and translational stop cassette. Expression of cre recombinase is directed to the 
pancreas by the use of pancreas-specific promoters such as Pdx-1 and Ptf1-p48. When 
the stop cassette is excised, the oncogenic allele is expressed at physiological levels 
from its endogenous promoter. Expression of oncogenic Kras in the mouse pancreas 
causes the complete spectrum of preinvasive PanINs described above, and with a 
prolonged latency the spontaneous development of pancreatic cancer with low 
penetrance (27).  
Additional mouse models have also been developed utilizing the incorporation of 
tumour suppressor gene mutations such as in the context of oncogenic Kras. The 
concomitant expression of a conditional point mutant Trp53 allele in this system 
accelerates tumorigenesis. In this model, PDA develops with a much shortened 
latency, and with all of the clinical and pathological features of advanced disease, 
including cachexia, haemorrhagic ascites, and metastases to the liver, lungs, 
peritoneum and lymph nodes (28).  The conditional deletion of the Ink4a/Arf locus or 
of Dpc4 also engenders rapid progression of metastatic PDA (29, 30). These tumour 
suppressors do not cause pancreatic cancer without the coordinate expression of 
oncogenic Kras. The observations in mouse models support the role of oncogenic 
Kras in the initiation of PDA and the tumour suppressors Ink4/Arf and Trp53 in 
disease progression, and fit well within the PanIN progression model. These mouse 
models provide a platform to study various facets of pancreatic cancer biology and are 
ideal to test therapeutic agents.  
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Utilizing genetically engineered mouse models in cancer biology and therapeutics  
To date, the vast majority of preclinical efficacy studies of various therapeutic agents 
have been carried out in xenograft models. Xenograft tumour models are generated in 
immunodeficient mice following the implantation of tumour cells or tumour tissue 
into ectopic (e.g. subcutis, renal capsule) or orthotopic sites. The commonly stated 
advantages of tumour xenografts are the ease of model generation and the fact that 
therapeutic assessment occurs in human cancer tissue as opposed to another species. 
Furthermore, patient-specific xenografts have recently been described as a means to 
develop personalized therapies for some malignancies (31, 32). Unfortunately, the 
results obtained from a number of xenograft studies (33, 34) have not translated well 
into the clinic (35, 36). 
Genetically engineered mouse (GEM) models are a promising alternative to xenograft 
models for biological and therapeutic investigations. GEM models are generated 
through the introduction of genetic mutations associated with particular human 
malignancies, and have been reviewed previously (37). One such example is the Kras 
and Trp53-driven models of pancreatic cancer described above. The initiating genetic 
lesion in a GEM, expressed through the use of conditional systems, occurs in the 
tissue that is relevant to the type of tumour being modelled. As a result, tumour 
initiation and progression occur in the correct cell type and in the relevant in situ 
environment. The result may be a pattern of expression whereby mutant cells are 
surrounded by normal cells, as is the case with tumour initiation in humans. In 
addition to the initiating molecular events, location of the preneoplasm within a 
particular cellular microenvironment or region of the organ may affect tumour 
7 
 
development. Primary PDAs, for instance, occur very frequently at the head of the 
pancreas, although the reasons for this are not understood. Tumour initiation in 
xenografts is very different, consisting of fully transformed, rapidly proliferating 
tumour cells grown in an environment that is not its normal milieu, and resulting in 
tumours that differ from corresponding human cancers. 
The kinetics of tumour development in vivo are generally considered to be rather 
slow, occurring over several years and requiring multiple rounds of selection for cells 
with additional mutations that render a survival or proliferative advantage. The result 
is a primary tumour that is heterogeneous and polyclonal. From the therapeutic 
standpoint, this variation is important because of inherent differences in the 
populations of tumour cells that may confer a more resistant phenotype to intervention 
than others. This variability is often lacking in xenografts, as the tumours develop 
very rapidly and are usually derived from homogeneous or oligoclonal populations of 
cells. GEM models that have a long latency to tumour development may possess such 
variability, and will permit the study of pathways and mechanisms of resistance to 
various therapies. Indeed, our Kras;Trp53 GEM model of ductal pancreatic cancer 
harbours an underlying chromosomal instability phenotype that may produce a similar 
genomic heterogeneity to that observed in primary human PDA. Conversely, certain 
GEM models in which cancers develop rapidly may circumvent some of these stages 
and may not be effective models of the human disease. 
One of the major drawbacks of xenograft models is the impairment of the immune 
system. Numerous studies have reported that the host immune system plays an 
important role in tumour development (reviewed in 38, 39). GEM models have the distinct 
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advantage of producing tumours with a well-developed stromal compartment. The 
stroma consists of extracellular matrix proteins, such as collagen, which lends rigidity 
to tumours, and a number of different cell types that are recruited during tumour 
development including activated fibroblasts and immune cells. This allows tumour-
microenvironment interactions to be modelled, in particular the role of non-cell 
autonomous processes and their relevance to tumour development and survival. In 
preclinical testing, understanding the effect of drugs on the tumour microenvironment, 
as well as the role of the immune system in the response to therapies, is of primary 
importance. GEM models can also be used to study the effect of immune-directed 
therapies. 
Accurate GEM models histologically mimic their cognate human malignancy. 
Tumours from xenograft models, as well as those from a number of early GEM 
models, are often histologically distinct when compared with tumours found in human 
malignancies. These differences in tumour structure and composition may skew the 
results of drug tests, and affect the response of the tumour to the therapy. For 
example, PDA xenograft tumours are often exquisitely sensitive to anti-angiogenic 
agents owing to the neovasculature that develops in xenografts (40, 41). However, there 
is less evidence that such a vascular composition is relevant in the cognate human 
tumour, as exemplified by the clinical failure of anti-vascular approaches in PDA. 
Tumour metastasis represents a major clinical problem for which there are few 
effective therapies. This process is often difficult to model in xenografts owing to the 
rapid growth of primary ectopic tumours, although orthotopic implantation followed 
by resection (42) and direct intravascular tumour cell injection can generate models of 
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distant spread. Nonetheless, xenograft models cannot recapitulate the myriad of 
processes required for metastasis from a primary tumour. GEM models that develop 
tumours that metastasize from the native site should, therefore, offer the optimal 
manner to study metastasis and evaluate therapeutics directed against this process. 
The development of approaches that accurately describe tumour burden and tumour 
biology during drug treatment is imperative for successful clinical translation. Given 
the multiple biological differences between xenografts and autochthonous human 
tumours, it is therefore not surprising that such methods are routinely developed in 
clinical investigation rather than during preclinical investigation. Indeed, GEM 
models should prove advantageous over xenograft models in this regard. For example, 
high resolution imaging modalities can be developed in GEM models to monitor 
therapeutic response. These include anatomic methods such as magnetic resonance 
imaging, computed tomography, and sonography, and functional methods that 
investigate tissue perfusion or metabolism. In contrast to PDA xenograft models, the 
Kras-driven GEM model of pancreatic cancer closely recapitulates the radiographic 
features of human PDA (43). Additionally, plasma proteomic profiling in GEM models 
can provide new candidates for tumour detection and monitoring in patients, as 
recently demonstrated with a mouse model of pancreatic cancer (44). As tumour tissue 
is readily available, GEM models enable the direct correlation between radiological 
responsiveness, drug levels, and molecular and cellular parameters. This is one of the 
least explored facets of therapeutic development, owing to the paucity of tumour 
tissue available from patients undergoing treatment. 
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Evidence supporting the usefulness of GEMs 
To date, GEM models of breast, lung and pancreatic cancer have been used in 
preclinical evaluations of therapeutic agents. Similar to clinical experience, lung 
adenocarcinomas arising as a result of mutant epidermal growth factor receptor 
(EGFR)-expression regressed on treatment with erlotinib and cetuximab (45, 46). In 
another study, the response of mammary tumours in p53-and Brca1-deficient mice to 
the chemotherapeutic agents doxorubicin, docetaxel and cisplatin was evaluated (47). 
Breast tumours in this model demonstrated sensitivity to the chemotherapeutic agents 
and acquired resistance in a manner that mimicked clinical experience (reviewed in 48). 
The use of GEM models of PDA, which do not respond to the chemotherapeutic 
gemcitabine, suggested a new paradigm in pancreatic cancer therapeutics by stromal 
depletion using hedgehog inhibitors (43). This type of analysis would not have been 
feasible in xenograft models given the paucity of stromal content. Therefore, these 
early results obtained with GEM models suggest they can provide similar therapeutic 
responses to those observed in clinical practice. 
The work presented here utilizes GEM models of pancreatic cancer to study the 
biology of the disease, as well as to study the effect of therapeutic agents. I have 
evaluated the relevance of the lysosomal protease cathepsin B in the initiation and 
development of PDA, and have identified cathepsin B as a potential therapeutic target 
of interest in pancreatic cancer. In addition I have evaluated the efficacy of 
farnesylthiosalicylic acid, a small molecule described as a Ras inhibitor, in the GEM 
model of PDA to determine its usefulness as a pancreatic cancer therapy.  
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CHAPTER I 
 
CATHEPSIN B PROMOTES THE PROGRESSION OF 
PANCREATIC DUCTAL ADENOCARCINOMA IN MICE 
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INTRODUCTION 
The cysteine cathepsin family of lysosomal proteases 
The cathepsins are a large family of lysosomal proteases. They are involved in a 
number of biological processes including protein turnover, antigen processing and 
immune responses, hormone activation, apoptosis and extracellular matrix 
remodelling (49, 50, 51). Cathepsins are classified according to catalytic site residues – 
cathepsins A and G are serine cathepsins, E and D are aspartate cathepsins, and the 
11cysteine cathepsins (B,C, F, H, K, L, O, S, V, W and X) comprise the largest 
subgroup and belong to the papain family of proteases (reviewed in 52).  
Cathepsin activity is tightly regulated, with all members of the family being 
synthesized as inactive zymogens. During transport to the endoplasmic reticulum, the 
prepeptide is removed. The propeptide is required for proper targeting, stability and 
folding (53-55). It also inhibits the activity of the enzymes by restricting access to the 
active site. The cathepsins are transported to lysosomes via the mannose-6-phosphate 
receptor pathway, where the procathepsins undergo proteolytic cleavage due to the 
reducing, acidic environment, giving rise to the active mature enzymes (56, 57).  
Cathepsins B and L are known to be ubiquitous and constitutive and are thought to 
participate in protein turnover. Other members of the cysteine cathepsin family 
exhibit more specific expression patterns: cathepsin S, for instance is expressed in 
immune cells and is involved in major histocompatibility complex II antigen 
presentation and cathepsin K is osteoclast-specific and involved in bone remodelling 
(reviewed in 58). The generation of knockout mice has allowed a more in-depth analysis of 
the role of cathepsins in various processes, and has highlighted some redundancies in 
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the family. Although cathepsin L knockout mice demonstrate phenotypes in skin and 
cardiac muscle, and cathepsin B-deficient mice are impaired in tumour necrosis factor 
alpha-induced hepatocyte apoptosis (59-61), these individual knockouts are viable. The 
combination of the two deficiencies, however, results in the apoptosis of cerebral and 
cerebellar neurons and death at 2-4 weeks (62).  
Disturbances in cathepsin activity lead to pathological conditions such as rheumatoid 
arthritis, cancer, osteoporosis, neurological disorders and lysosomal storage diseases, 
and are thus being studied as therapeutic targets for a number of diseases(reviewed in 63, 
64).  
Cathepsin B  
Structure and activation 
Cathepsin B is a ubiquitous member of the cysteine cathepsin family, and is 
considered a housekeeping gene. In humans, the gene is located on chromosome 
8p22, and consists of 12 exons (65). The inactive protein consists of 339 amino acids 
(43 kda) and the active single chain form is 31kda (57).  Structurally, cathepsin B 
consists of two distinct domains, the left-hand “L” domain and the right-hand “R” 
domain. The L domain consists mostly of alpha-helices and the R domain is 
composed of a beta-barrel motif. The amino and carboxy termini function to hold the 
domains together. The protein is approximately disc shaped with an obvious incision 
representing the active site cleft. Catalytic residues in the active site are cysteine 108, 
histidine 278 and asparagine 298 (Fig I1.1A). In the proenzyme, the propeptide 
occupies the active site and prevents its accessibility to substrates (Fig I1.1B) (66). 
Cathepsin B is an endopeptidase like most other members of the family. In addition,  
 Fig I1.1 Crystal structure of cathepsin B. The diagram of procathepsin B (A) 
depicts the propeptide in grey. Catalytic residues are depicted – the active site Cys108 
is in yellow, His278 in purple, and Asn298 in pink. Histidine residues on the 
occluding loop are depicted in purple. Structure obtained from MEROPS – the 
peptide database C01.060  (A). The active site cleft is visible in this depiction of the 
three-dimensional structure of cathepsin B, along with its occupation by the 
propeptide.  Image obtained from Cygler et al. Structure 1996:4(4) (B). 
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however, it is also a carboxypeptidase, due to the presence of an occluding loop 
formed from residues 104 – 126. Two cysteine residues, cys108 and cys119, form a 
disulphide linkage that encloses the included residues in a circle, and the histidine 
residues his110 and his111 serve to stabilize the terminal carboxylate of a peptide. 
Together, this structure accounts for the dipeptidyl carboxypeptidase activity (reviewed in 
67). 
Activation of the enzyme is precipitated by a decrease in pH. This decrease 
substantially weakens the interactions between the active cleft and the propeptide (68). 
Glycosaminoglycans, which facilitate autoactivation, are also capable of inducing a 
conformational change resulting in the weakening of the propeptide-active cleft 
interaction (69). The occluding loop of cathepsin B is involved in displacing the 
propeptide once it is less tightly bound to the active site (70). Since propeptides exhibit 
a small amount of intrinsic catalytic activity, this may be sufficient to initiate a chain 
reaction of propeptide cleavage. However, other proteinases may also have a role in 
initiation of activation. Once the chain is begun, the process rapidly continues due to 
the increasing numbers of active molecules (71).  
Cathepsin B in cancer 
Cathepsin B expression is upregulated in a number of human malignancies. Cathepsin 
B levels in serum and tumour tissue are under investigation as prognostic indicators in 
a variety of tumour types including colon , endometrial , non-small cell lung, 
glioblastoma, pancreatic cancer, breast carcinoma and melanoma which are 
summarized in Table I1.1 (72-79). 
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Cancer type Relation of cathepsin B expression to outcome 
Colon cancer Associated with higher risk of mortality. 
Endometrial cancer Predictive of aggressive tumour behaviour. 
Non-small cell lung cancer Associated with poor outcome. 
Glioblastoma Strong predictor of survival. 
Gastric cancer Associated with advanced tumour stages and 
progressive disease. 
Pancreatic adenocarcinoma Strong prognostic marker in resectable pancreatic 
cancer, predictor for early recurrence after resection. 
Breast carcinoma Good prognostic indicator in lymph node-negative 
patients. 
Oral cancer Prognostic marker – relationship between expression 
levels and invasive and metastatic growth. 
Melanoma May serve as a prognostic factor in advanced disease 
Table I1.1 Correlation of cathepsin B in serum or tumour tissue with disease 
outcome  
Upregulation occurs via several different mechanisms. In oesophageal and gastric 
adenocarcinomas, a novel amplicon has been identified that results in the 
overexpression of cathepsin B (80, 81). Tumour cells express cathepsin B transcript 
variants, through alternative promoters and splicing (82, 83).  In fact, cathepsin B 
transcripts lacking exon 2 appear to be more efficiently translated, and may be 
responsible for the increased expression of cathepsin B in a number of human 
malignancies (65, 84, 85). Cathepsin B transcription appears to be controlled by the Sp1 
and Ets1 transcription factors in cancer, with expression levels correlating with levels 
of Sp1 in glioma cells (82, 86, 87).  In addition, the mRNA stability of cathepsin B can be 
altered – for instance, phorbol ester treatment of the HL60 human leukaemia cell lines 
results in increased mRNA half-life on differentiation into macrophages (88).  
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Cathepsin B is not just upregulated but also mislocalized. Expression in tumour cells 
is in lysosomal and endosomal vesicles, but it is also on the plasma membrane and 
secreted into the extracellular space. So far, cathepsin B is the only cysteine cathepsin 
that has been localized to a membrane microdomain. Procathepsin B binds directly to 
S100A10, the light chain of the annexin II heterotetramer (AIIT), and this interaction 
mediates the localization of cathepsin B to caveolae of human colon carcinoma cells 
(89, 90). The localization of cathepsin B to caveolae also appears to be influenced by 
mutant Kras, which results in increased pericellular activity (91). In addition, 
interactions of cells with extracellular matrix components such as collagen I increase 
cathepsin B secretion as does decreased extracellular pH, the latter potentially through 
lysosomal exocytosis (92, 93).  
Cathepsin B, through the degradation of extracellular matrix components such as 
collagen IV, laminin and fibronectin, is thought to participate in malignant 
progression. This degradation occurs either directly, or through the activation of 
proteolytic cascades on the cell surface. Proteases such as urokinase plasminogen 
receptor (uPA) and its receptor uPAR, and the matrix metalloproteases MMP-2 and 
MT1-MMP are localized to caveolae (94-96). Cathepsin B can activate uPA and MMPs, 
thus initiating protease cascades that contribute to matrix degradation and the 
tumorigenic process (Fig I1.2).  
Cathepsin B in mouse models of cancer 
Mouse models of islet, mammary and intestinal carcinomas have elucidated the 
importance of cathepsin B in various tumour types. In the RIP-Tag model of islet 
carcinogenesis, lack of cathepsin B retards tumour growth and impairs proliferation  
  
 
Fig I1.2 Cathepsin B activates proteases extracellularly. Cathepsin B may be 
exported in cancer cells. One mechanism for this occurrence is through interactions 
with Annexin II heterotetramers. Once cathepsin B is activated outside the cell, it is 
involved in the initiation of proteolytic cascades, by activating MMPs and converting 
Pro-Urokinase plasminogen activator (Pro-UPA) to active UPA.  
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and invasion (97, 98). The overexpression of cathepsin B in the polyoma middle T-
induced mammary carcinoma model enhances tumour progression and metastasis, 
with increased immune infiltration and angiogenesis (99).  Cathepsin B loss in the 
mouse mammary tumour virus – PyMT model impaired the development of high-
grade carcinomas, with a significantly decreased tumour proliferation (100). The 
genetic ablation of cathepsin B in the Adenomatous Polyposis Coli (APC) model 
results in decreased polyposis (101). Cathepsin B loss impinges upon various facets of 
tumour development including initiation, proliferation, apoptosis, angiogenesis and 
metastasis. The contribution of cathepsin B to tumour development and metastasis is 
not solely cell autonomous. Indeed, tumour-associated stromal cells such as 
fibroblasts, macrophages and neutrophils express cathepsin B (58), and a role for  
microenvironmental cathepsin B in metastasis has been previously demonstrated in 
vivo in the transgenic MMTV-PyMT model of mammary carcinoma (102). In addition, 
cathepsin B from tumour-associated macrophages is an important contributor  towards 
tumour growth, angiogenesis and invasion (103).  
To examine the role of cathepsin B in the initiation and progression of PDA, the 
oncogenic Kras-driven mouse models of pancreatic cancer were utilized, concomitant 
with genetic ablation of cathepsin B. In these models, cathepsin B expression and 
cathepsin activity are upregulated in preinvasive and invasive stages of disease. As 
shown, Cathepsin B deficiency leads to decreased proliferation in PanINs and confers 
a significant survival advantage in mice that develop PDA. Additionally, pancreatic 
carcinomas lacking cathepsin B retain a proliferative defect that is consistent with that 
observed in early-stage disease. Cathepsin B loss also affects metastasis of PDA to the 
liver with a significant reduction in the burden of liver metastases. In addition, 
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cathepsin B null mice exhibit trends towards decreased incidence of liver metastasis 
and increased incidence of lung metastasis. Loss of cathepsin B expression correlates 
with decreased phospho-ERK and decreased proliferation of pancreatic cancer cell 
lines in subcutaneous allografts. Finally, use of a non-cell permeable broad-spectrum 
cysteine protease inhibitor in combination with Gemcitabine in vivo increases survival 
of tumour-bearing mice. Taken together, these results support cathepsin B as a 
therapeutic target in PDA.  
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MATERIALS AND METHODS 
Mouse strains  
The LSL-KrasG12D, LSL-Trp53R172H, Trp53flox/flox, Pdx-1-Cre and cathepsin B null 
strains of mice have been previously described (27, 28, 104, 105). These strains of mice 
were interbred to ensure a mixed C57BL6/129Sv background for survival studies. 
Mice were housed and maintained, and experiments were conducted, in compliance 
with UK home office regulations.  
Generation of experimental animals 
1. LSL-KrasG12D; Cathepsin B; Pdx-1-Cre: LSL-KrasG12D; Cathepsin B mice 
were bred with Cathepsin B; Pdx-1-Cre to generate LSL-KrasG12D; Pdx-1-
Cre; Cathepsin B+/+ and LSL-KrasG12D; Pdx-1-Cre; Cathepsin B-/- 
offspring which were utilized for timepoint analysis of disease burden. 
2. LSL-KrasG12D; Trp53flox/flox; Cathepsin B; Pdx-1-Cre: LSL-KrasG12D; 
Trp53flox/flox; Cathepsin B and Trp53flox/flox; Cathepsin B; Pdx-1-Cre 
parents were mated to generate LSL-KrasG12D; Trp53flox/flox; Pdx-1-Cre; 
Cathepsin B+/+ and LSL-KrasG12D; Trp53flox/flox; Pdx-1-Cre; CathepsinB-/- 
offspring for survival studies 
3. LSL-KrasG12D; Trp53R172H; Cathepsin B; Pdx-1-Cre: LSL-KrasG12D; 
Trp53R172H; Cathepsin B mice were interbred with Cathepsin B; Pdx-1-Cre 
mice. The offspring of interest were LSL-KrasG12D; LSL-Trp53R172H; Pdx-
1-Cre; Cathepsin B+/+ and LSL-KrasG12D; LSL-Trp53R172H; Pdx-1-Cre; 
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Cathepsin B-/-, which were utilized for survival and further tumour 
studies. 
4. LSL-KrasG12D; Trp53R172H; Pdx-1-Cre: LSL-KrasG12D; Trp53R172H and  
Pdx-1-Cre mice were bred together to generate experimental animals used 
for therapeutic studies. 
Reagents  
Avidin-biotin blocking kits (SP-2001), signal amplification kits (PK-6200), DAB 
substrate kits (SK-4100) and peroxidise-conjugated secondary antibodies for 
immunohistochemistry were obtained from Vector labs. Prosense 680 was obtained 
from VisEN Medical. E64 was obtained from Sigma-Aldrich.  Secondary antibodies 
for western blotting were obtained from Jackson Immunoresearch. EZ-link Sulfo-
NHS-SS-Biotin and neutravidin agarose from Pierce was obtained from Thermo 
Fisher. Tissue culture reagents were obtained from GIBCO. E64 (E3132) was 
obtained from Sigma-Aldrich.  
Immunohistochemistry  
Paraffin-embedded mouse tissue sections were dewaxed in 100% xylene (2x 
5minutes), and were then rehydrated through an ethanol series (5 minutes each in 
100%, 96%, 80% and 70% ethanol) followed by phosphate-buffered saline (PBS). 
Antigen retrieval was heat-mediated using boiling citrate buffer (10mM, pH 6.0). 
After cooling, endogenous peroxidise activity was blocked by incubation in 3% 
hydrogen peroxide for 15 minutes. The slides were then blocked for 30 minutes at 
room temperature in 10% serum + 1% BSA, followed by avidin-biotin blocking. 
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Primary antibodies were used at the dilutions indicated below in blocking buffer, and 
were incubated overnight at 4°C.  
Slides were washed twice with TBS-T and incubated with biotinylated secondary 
antibodies at room temperature for 30 minutes. Signal amplification was carried out 
with Vectastain ABC reagents for 30 minutes, and slides were incubated with 
diaminobenzidine (HRP-based detection) until suitable signal developed. The slides 
were rinsed in tap water and counter-stained with Harris haematoxylin. They were 
then dehydrated through an ethanol series into xylene and coverslipped with permount 
mounting medium.  
Antibody Source Dilution 
Cathepsin B  R&D Biosystems 1:50 
Cathepsin L  R&D Biosystems 1:50 
Alpha-smooth muscle  actin Abcam 1:200 
Phospho-histone H3 Cell Signaling 1:100 
Ki67 Neomarkers 1:200 
CD31 Santa Cruz Biotechnologies 1:100 
Phospho-ERK (Thr202/Tyr204) Cell Signaling 1:100 
Table M 1.1: Antibodies for Immunohistochemistry 
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Masson’s trichrome staining 
 Tissue sections were deparaffinised in xylene as described above. Sections were 
treated with picric acid for 30 minutes, and were then washed in running tap water. 
The tissue was stained with Weigert’s Iron haematoxylin solution for 5 minutes and 
washed briefly in running water. Sections were then treated in 2% acid alcohol to 
differentiate, washed in running tap water and stained with acid fuchsin for 10 
minutes. After rinsing in deionised water, the tissue was treated with 
phosphomolybdic acid for 5 minutes and then stained with methyl blue for 5 minutes. 
The slides were rinsed in deionised water, differentiated in 1% acetic acid and 
dehydrated rapidly in two changes of 100% ethanol and xylene, and mounted using a 
xylene-based mounting medium.   
In vivo measurement of cathepsin activity  
Prosense 680 was diluted in 1X PBS according to the manufacturer’s instructions 
(1.35 mls of 1X PBS added to 150 µl of probe). The probe was equilibrated to room 
temperature and injected at a concentration of 80nM/kg intravenously into the tail 
vein.  After 24 hours, mice were sacrificed and the pancreas and brain were harvested. 
Fluorescence signal was detected using the IVIS 200 (Caliper Life Sciences, MA), 
and signal intensity was quantified using Living Image 3.2 as a measure of arbitrary 
units per gram of tissue.  Brain tissue was used as a negative control. 
Derivation of tumour cell lines  
The establishment of cell lines from mouse pancreata has been previously described 
(106). The pancreatic cancer cell lines used in this study were established by an 
abbreviated version of this protocol. In brief, mice were sacrificed and tumour pieces 
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were harvested into buffered G solution (HBSS + Penicillin/streptomycin, fungizone, 
0.9g/L glucose). The tumour pieces were minced in 1ml of 0.25% trypsin, and were 
incubated at 37°C for 10 minutes. Trypsin was quenched in DMEM + 10% FBS. 
Cells were centrifuged, washed three times in G solution, and plated onto BD biocoat 
collagen plates in serum-free ductal medium (DMEM F-12, 1.22 mg/ml nicotinamide, 
5mg/ml glucose, 5% ITS+, 100µg/ml gentamicin, 5% Nu-serum IV, fungizone, 25 
µg/ml bovine pituitary extract, 20ng/ml epidermal growth factor, 50nM 3,3’5-
Triiodo-L-thyronine, 1µM dexamethasone, 100ng/ml cholera toxin). Cells were 
maintained on collagen for two passages and were then transferred to plastic. Once 
successfully established on plastic, cell lines were maintained in DMEM + 10% FBS.  
Generation of mouse embryonic fibroblasts 
Cathepsin B null mouse embryonic fibroblasts (MEFs) were obtained from E13.5 day 
embryos. Embryos were dissected from pregnant females, the internal organs and 
heads were removed and the tissue was chopped up in 0.25% trypsin. Following a 45 
minute incubation at 37°C, the trypsin was quenched and the cells were suspended by 
pipetting in DMEM + 10% FBS, and were plated onto 15 cm dishes.  
Surface biotinylation of cell lines 
Biotin labelling of surface proteins was carried out using 0.5 mg/ml of EZ-Link-
Sulfo-NHS-SS-Biotin. The reagent was prepared fresh immediately prior to use. Cells 
were washed with cold 1X PBS and were labelled for 30 minutes at 4°C. Unlabelled 
cells to be used as a negative control were incubated with 1X PBS. Unbound biotin 
was quenched with 100mM glycine. Cells were rinsed and lysed with RIPA buffer. 
Lysates were incubated with neutravidin beads for 1 hr at 4°C. The beads were 
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washed in cold 1X PBS and boiled in SDS loading buffer to elute bound protein, and 
proteins were analyzed by western blotting. 
Quantification of proliferation  
Proliferation in PanINs was quantified as percentage of Ki67 positive cells. Tissue 
sections were stained for Ki67 and all PanINs on a given section were quantified by 
enumeration of positive and negative nuclei. Tumour proliferation was quantified as a 
measure of phospho-histone H3 positive nuclei in five 20X fields. Proliferation in 
allografts was quantified by measuring the number of Ki67 positive cells per 20x 
field.  
Tumour analysis 
Areas of necrosis were measured using Imagescope, and were represented as 
percentage of total tumour area. Mean vessel density (MVD) was measured by 
staining sections for CD31, and enumerating the number of vessels in five 40X fields. 
Area of liver and lung metastases was measured using Imagescope. 
Protein extraction from tumour tissue 
Tumour fragments harvested for protein lysates were snap-frozen in liquid nitrogen. 
Tissue was lysed in SDS lysis buffer containing protease and phosphatase inhibitors 
and centrifuged to remove debris.  
Cloning and Transfection  
The mouse cathepsin B cDNA (107) was isolated from the pSG5 backbone using 
BamHI and EcoRI and was cloned into the pBabehygro expression vector. The 
resulting expression plasmids were sequenced to verify cathepsin B cDNA integrity. 
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Cells were transfected with pBabehygro or pBabehygro-Cathepsin B using 
lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Serum-
free Opti-MEM was combined with 5µl lipofectamine and 2µg DNA to a final 
volume of 200µl, which was added to cells drop-wise. After 24 hours, the medium 
was replaced and cells were selected with 200ug/ml hygromycin for 7 days to select 
clones stably-expressing cathepsin B.  
Cell culture  
Cell lines derived from tumours were maintained in DMEM + 10% FBS. For 
harvesting protein, 2 x 106 cells were plated on 10cm dishes, grown overnight and 
were fed with DMEM + 1% FBS for 24 hours before use. Protein lysates were 
obtained using SDS lysis buffer. Culture supernatants were harvested and 
concentrated using Millipore centrifugal filter units.  
Proliferation assays 
Proliferation assays were set up by trypsinizing cells and seeding them at 2.5 x 105 
cells in triplicate in 12-well dishes in either DMEM + 10% FBS or DMEM + 1% 
FBS. Cells were fed daily and cell number was determined on days 1, 3, 5 and 8 using 
a Z2 Coulter Counter (Beckman Coulter).  
Soft agar assays 
Soft agar assays were set up in 6 cm dishes. Low melting point agarose was dissolved 
at 2% in DMEM. This stock was diluted to 0.8% agarose, 4mls was plated onto 6 cm 
dishes and allowed to solidify for 30 minutes. Cells were trypsinized, and 2 x 104 cells 
were suspended in 0.4% low melting point agar and were layered over the 0.8% agar. 
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The agarose was allowed to set before plates were transferred to a 37°C incubator 
overnight. The next day, cells were fed with DMEM + 10% FBS. Colonies were 
allowed to develop for three – four weeks, and the cells were fed twice weekly during 
this period.  
Cytokine arrays 
Analysis of cytokine profiles was conducted using the RayBio mouse cytokine 
antibody array 6 (AAM-CYT-6) from RayBiotech Inc. The assay was conducted as 
described by the manufacturer. Snap-frozen tissue fragments and cell lines were lysed 
in 1X RayBio cell lysis buffer with added proteinase inhibitors (Roche), and protein 
concentration was quantified. Pooled tumour samples were prepared by mixing 50 µg 
protein each from five KPC;B+/+ and five KPC;B-/- tumours  to give a total of 250 
ug protein for each cohort. Samples from cell lines were similarly pooled – 100 ug 
each for a total of 300 ug each for cathepsin B-null and cathepsin B-reconstituted 
tumour lines. Pooled samples were diluted to a total volume of 2mls in 1X blocking 
buffer. 
Array membranes were blocked with 3mls 1X blocking buffer at room temperature 
for 30 minutes. Blocking buffer was decanted, the samples were added to the 
membranes and were incubated at 4°C overnight with gentle rocking. The membranes 
were washed three times with 1X wash buffer I for five minutes each at room 
temperature, followed by two five-minute washes with 1X wash buffer II at room 
temperature. 
Biotin-conjugated primary antibody solution was prepared by diluting it in 4mls 1X 
blocking buffer, 2 mls of the working solution was added to each membrane and 
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incubated at room temperature for 2 hours. This incubation was followed by repeated 
washes as described above. HRP-conjugated streptavidin was diluted 1000-fold in 1X 
blocking buffer, 3mls of the working solution was added to each membrane, 
incubated for 2 hours at room temperature and washed as described above. Detection 
was by chemiluminescence using the provided detection reagents and X-ray film 
(Amersham). The film was scanned using a GE Image Scanner III, and the spots were 
quantified using ImageQuant software.  
Interleukin-6 enzyme-linked immunosorbent assay (ELISA) 
Interleukin-6 levels in cells and tissue were measured using the Quantikine mouse IL-
6 immunoassay (R&D systems, M6000B). Cells and tissues were lysed using 1X cell 
lysis buffer (Cell Signaling, 9803) with added protease inhibitors. Five tumour 
fragments each were assayed from the KPC;B+/+ and KPC;B-/- cohorts. 50µg of 
protein was loaded for each sample in a volume of 50 µl, with assays being done in 
triplicate. 
Standard dilutions were prepared in calibrator diluents ranging from 0 pg/ml to 
500pg/ml. 50 µl of assay diluents was added to each well, followed by 50 µl of 
standards, control and samples in triplicate. The plate was mixed gently and allowed 
to incubate at room temperature for 2 hours, followed by 5 washes with 400 µl each 
of wash buffer. Wash buffer was carefully decanted from all wells before proceeding 
to the next step. 100 µl of enzyme-linked IL-6 polyclonal antibody was added to each 
well and incubated for two hours at room temperature, followed by washes as 
described above to remove unbound antibody. Signal was generated by incubating 
with 100 µl of substrate solution for 30 minutes at room temperature in the dark, and 
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the reaction was halted with the acidic stop solution. The optical density was read 
using the Tecan Infinite M200 microplate reader. Sixteen spots were read per well at 
450nm, with a background correction of 570nm. Optical density values were plotted 
on the standard curve to generate interleukin-6 concentrations.  
Ras-GTP assays 
Ras activity was measured with a kit (Millipore) following the manufacturer’s 
instructions. Cells were rinsed twice with ice-cold 1X PBS and lysed in ice-cold 
Mg2+ lysis buffer (25mM Hepes pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 10mM 
MgCl2 and 2% glycerol). Lysates were incubated with 10 µl Raf-1 RBD agarose 
beads for 30 minutes at 4°C. The beads were washed carefully three times with cold 
lysis buffer, and were boiled in SDS loading dye to elute proteins. Ras-GTP levels 
were measured by western blotting.  
Western blotting  
Proteins were boiled in SDS loading buffer, separated at 80 – 100V on 4-12% Nupage 
gels (Invitrogen) using MES running buffer (Invitrogen). Proteins were transferred 
onto PVDF membranes (Millipore) in transfer buffer (25mM Tris, 192mM glycine, 
20% ethanol) at 70V for 2.5 hours. Membranes were blocked for one hour with 5% 
milk in TBST (10mM Tris, 150mM NaCl, 0.1% Tween-20) and were incubated with 
relevant primary antibodies at 4°C overnight. Membranes were washed with TBST  
Antibody Source Dilution 
Cathepsin B  R&D Biosystems 1:1000 
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Cathepsin L  R&D Biosystems 1:1000 
Actin (I-19) Santa Cruz Biotechnologies 1:5000 
EGFR  Cell Signaling 1:1000 
ERK  Cell Signaling 1:1000 
Stat3 (Tyr705) Cell Signaling 1:1000 
Phospho-Akt (Ser 473) Cell Signaling 1:1000 
Phospho-Rsk (Thr359/Ser363) Cell Signaling 1:1000 
Phospho-S6 (Ser 240/244) Cell Signaling 1:1000 
Cyclin D1 Santa Cruz Biotechnologies 1:1000 
Phospho-MEK (Ser 217/221) Cell Signaling 1:1000 
Ras (Ras10) Millipore 1:10,000 
MKP1 Santa Cruz Biotechnologies 1:1000 
MKP2 Santa Cruz Biotechnologies 1:1000 
MKP3 Santa Cruz Biotechnologies 1:1000 
Spry2 Abcam 1:1000 
Her2 Cell Signaling 1:1000 
cKit Santa Cruz Biotechnologies 1:1000 
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PDGFRα Santa Cruz Biotechnologies 1:1000 
Table M1.2: Antibodies for Western blots 
and incubated with HRP-conjugated secondary antibodies for 45 minutes at room 
temperature. Signal detection was by chemiluminescence using X-ray film. 
Densitometry analysis was conducted using Adobe Photoshop.  
Subcutaneous allografts  
Cell lines were grown to confluence, trypsinized, washed in PBS and resuspended  at 
1 x 107 cells/ml in sterile PBS. Mice were shaved and cells were injected 
subcutaneously into the flanks of C57Bl6 and cathepsin B null mice, with cathepsin B 
null cells injected into the left flank and cathepsin B expressing cells into the right 
flank. Tumour growth was followed using callipers. 
E64 survival study  
Screening and ultrasound of mice was performed as has been previously described 
(43), and will be described in detail in chapter II. Mice were enrolled on study when 
tumours reach a mean diameter of 6-9 mm. E64 was prepared in saline as a 5mg/ml 
stock solution, Mice were dosed at 50mg/kg daily by intraperitoneal injection until 
endpoint. Endpoint included greater than 20% weight loss, development of ascites or 
obvious signs of ill health. 
Statistical Analysis  
Kaplan-Meier statistics for survival curves were conducted using the Gehan-Breslow-
Wilcoxon test. Proliferation, cathepsin activity, phospho-ERK, necrosis and mean 
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vessel density data were analyzed by Mann-Whitney U test, and metastasis incidence 
data were evaluated by Fisher’s exact test. Graphpad prism software was used to 
conduct statistical analysis. 
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RESULTS 
Cathepsin B expression and cathepsin activity are increased during disease 
progression  
To evaluate cathepsin B levels during the development of PDA, cathepsin B 
expression was assessed in mouse tissue. Cathepsin B in the normal pancreas was 
confined to punctate staining in the acini (Fig 1.1A, arrows), and low level expression 
in ducts (Fig 1.1A, arrowheads). In contrast, cathepsin B was highly elevated in 
PanINs, with the entire apical cytoplasm staining strongly positive (Fig 1.1B, 
arrowheads). It should be noted that staining in some PanINs was restricted to the 
perinuclear area of the cell (data not shown). In addition, some stromal cells also 
stained positively for cathepsin B (Fig 1.1B, arrows). Cathepsin B expression in PDA 
was strongly positive and distributed throughout the cytoplasm (Fig 1.1C). Tissue 
from a cathepsin B null mouse did not exhibit positivity, confirming the specificity of 
the stain (Fig 1.1D). In vivo cathepsin activity was increased in PanIN (p=0.0040) and 
tumour (p=0.0159) compared to normal pancreas (Fig 1.1E). 
Cathepsin B expression in pancreatic cancer cell lines is mislocalized 
A panel of pancreatic cancer cell lines derived from mice was evaluated for cathepsin 
B expression. Cathepsin B was expressed in all cell lines, as expected. Protein from a 
cathepsin B-null MEF line was used as a negative control (Fig 1.2A). Cathepsin B 
was secreted from these cell lines, and was detectable in conditioned medium (Fig 
1.2A). In addition, enrichment of surface proteins by biotinylation followed by 
neutravidin pull-down showed that active cathepsin B is localized on the plasma 
membrane of tumour cell lines (red arrows, lanes 3). There was no cathepsin B in the  
 Figure 1.1: Increased cathepsin B expression during pancreatic cancer 
progression. Immunohistochemistry for cathepsin B shows that normal pancreatic 
tissue exhibits punctate staining in the acini (arrows) and low level staining in ducts 
(arrowheads) (A). Cathepsin B expression is greatly increased in PanINs 
(arrowheads). Positive staining is also seen in stromal cells (arrows) (B).  Tumour 
cells are positive for cathepsin B (C). Cathepsin B null tissue is used as a negative 
control (D). (Scale bar = 100µm).Cathepsin activity is also increased in vivo (E). The 
Mann-Whitney test was used to determine differences in activity. 
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 Figure 1.2: Cathepsin B is mislocalized in pancreatic cancer cell lines. Cathepsin 
B is universally expressed in lysates from a panel of PDA cell lines (A). In addition, it 
is also secreted into the medium, although secreted cathepsin B is not active (A). A 
cathepsin B null MEF line is used as a negative control (A). Surface biotinylation of 
tumour cell lines shows that active cathepsin B is present at the plasma membrane (B, 
lanes 3, red arrows). Cathepsin B is not present in the unbiotinylated controls (B, 
lanes 1, black arrows). EGFR is used as a positive control (B, lanes 3). Lanes 2 and 4 
are input controls (B).  
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unbiotinylated control lanes, demonstrating the specificity of signal (black arrows, 
lanes 1) (Fig 1.2B).  
Cathepsin B loss leads to decreased early PanIN burden and sustained decreased 
proliferation in PanINs 
Cathepsin B null mice were used to evaluate the role of cathepsin B in the initiation of 
PDA (105). These cathepsin B-deficient mice were crossed to mice harboring the LSL-
KrasG12D allele and mice harbouring a transgenic Pdx-1-Cre recombinase (6) to direct 
expression of oncogenic Kras to the pancreas. Pancreata from mice with the relevant 
genetic combinations were examined at different time points for disease burden 
including reactive acini and PanINs. Cathepsin B ablation did not prevent PanIN 
formation, and preneoplasms were morphologically similar regardless of cathepsin B 
status (data not shown). At two months, there was no significant difference in disease 
burden between pancreata from LSL-KrasG12D; Pdx-1-Cre; Cathepsin B+/+ 
(KC;B+/+) and LSL-KrasG12D; Pdx-1-Cre; Cathepsin B-/- (KC; B-/-) mice. The 
pancreatic lobules in KC;B+/+ mice were 54.42% (+/-6.715) normal and 31.23% (+/- 
4.279) reactive, consisting of acinar-to-ductal metaplasia. 14.35% (+/-4.279) of 
lobules had PanIN1s. There were no PanIN2s and PanIN3s at this time point. In the 
KC;B-/- cohort, the pancreas consisted of 69.16% (+/- 3.993) normal lobules. 21.98% 
(+/- 3.645) of lobules contained reactive areas, and 8.862% (+/- 2.721) of lobules 
carried PanIN1s. As with the KC;B+/+ cohort, there were no higher grade PanINs 
(Fig 1.3A). 
 
  
Figure 1.3: Loss of cathepsin B causes decreased early PanIN burden and 
decreased proliferation in PanINs. Analysis of disease burden reveals that at two 
months, cathepsin B loss does not affect reactive acini or PanIN load. At 4-6 months, 
pancreata from cathepsin B null mice have more normal lobules and decreased 
PanIN1-containing lobules. At 8-10 months, there is no difference between cathepsin 
B null and cathepsin B-expressing pancreata. (A). Quantification of proliferation in 
PanINs by Ki67 immunohistochemistry reveals that loss of cathepsin B causes a 
significant decrease in proliferation in 4-6 month old and 8-10 month old mice.  At 
two months, there is a trend towards decreased proliferation, although this is not 
statistically significant (B). The Mann-Whitney test was used to analyze disease 
burden and proliferation data.  
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At 4-6 months, pancreata from the KC;B-/- cohort had a higher fraction of normal 
lobules (43.75%, +/-2.969) compared to the KC;B+/+ cohort (p=0.0002). In addition, 
there was a decrease in the number of PanIN 1-bearing lobules in the KC;B-/- cohort 
(23.33%, +/- 2.050) compared to the KC;B+/+ cohort (41.77%, +/- 6.519) (p=0.0178). 
There was no difference in reactive lobules or higher PanIN grades. At 8-10 months, 
there was no significant difference between the two cohorts in any of the disease 
grades analysed, although the KC;B-/- cohort tended towards decreased PanIN1 
compared to the KC;B+/+ cohort (Fig 1.3A). 
Cathepsin B loss led to decreased proliferation in PanINs.  At two months, PanINs 
from KC;B-/- pancreata displayed a trend towards decreased proliferation (3.498 ± 
1.998 mean percentage proliferation), though not statistically significant, compared to 
LSL-KC;B+/+ (5.267 ± 2.125) pancreata (Fig 1.3B). At 4-6 months, the difference in 
PanIN proliferation was statistically significant in KC;B-/- pancreata (6.095 ± 3.064) 
compared to KC;B+/+ (11.04 ± 3.756, p=0.0006) (Fig 1.3B). This effect on 
proliferation persisted at 8-10 months, with KC;B-/- mice (5.919 ± 1.940) exhibiting a 
>50% reduction in proliferation compared to KC;B+/+ (12.75 ± 3.201, p=0.0004) 
mice (Fig 1.3B). There was no difference in pancreatic apoptotic index between 
cohorts (data not shown).  
Loss of cathepsin B prolongs survival in advanced models of pancreatic cancer 
Following the initial observation of decreased proliferation in preinvasive lesions, the 
role of cathepsin B in pancreatic cancer progression was studied in mice. To 
accelerate the development of pancreatic cancer, the oncogenic KrasG12D allele was 
combined with a conditional point-mutant Trp53R172H allele, and a Trp53flox/flox allele,  
 Figure 1.4: Cathepsin B loss extends survival of mice with PDA. KPC;B-/- mice 
have a median PDA-free survival of 199 days, a significant extension over KPC;B+/+ 
mice with a median of 168 days (p=0.0113)  (A). Lack of cathepsin B also imparts a 
significant survival advantage in the context of Trp53flox/flox alleles, with a median 
survival of 65 days for KPflC;B-/- mice compared to 53 days for the KPflC;B+/+ 
cohort (p=<0.0001) (B). In both backgrounds, the earliest PDA-related morbidity in 
the cathepsin B cohorts was delayed, indicating that tumour onset may be delayed. 
Kaplan-Meier statistics were conducted using the Gehan-Breslow-Wilcoxon test. 
40 
 
41 
 
as previously described (28, 104). Once again, cathepsin B null mice were bred into 
these combinations of alleles and Pdx-1-cre was utilized to direct expression of the 
mutations to the pancreas to generate cohorts of mice with the various allelic 
combinations.  
Kaplan-Meier statistics demonstrated that LSL-KrasG12D; LSL-Trp53R172H; Pdx-1-Cre; 
Cathepsin B-/- (KPC;B-/-) mice had a significantly increased PDA-free survival with 
a median of 199 days. In contrast, the median PDA-free survival of LSL-KrasG12D; 
LSL-Trp53R172H; Pdx-1-Cre; Cathepsin B+/+ (KPC;B+/+) was 168 days (p=0.0113). 
Cathepsin B loss delayed the onset of PDA, as the earliest case of PDA-related 
morbidity in the KPC;B-/- cohort was 127 days, compared to 90 days in the 
KPC;B+/+ cohort (Fig 1.4A). The survival advantage imparted by cathepsin B loss 
was also observed in LSL-KrasG12D; Trp53flox/flox; Pdx-1-Cre; Cathepsin B-/- 
(KPflC;B-/-) mice, with a median survival of 65 days, compared to 53 days in the 
LSL-KrasG12D; Trp53flox/flox; Pdx-1-Cre; Cathepsin B+/+ (KPflC;B+/+) mice 
(p=<0.0001) (Fig 1.4B).  
Proliferation in tumours is decreased as a result of cathepsin B loss 
Further analysis of cathepsin B loss on tumours was conducted in the context of the 
Trp53R172H allele, as this model is of more physiological relevance. KPC;B-/- mice 
developed the expected features of PDA, including hemorrhagic ascites and liver and 
lung metastases. The morphology of PDA in the KPC;B-/- cohort was comparable to 
the KPC;B+/+ cohort, including histological patterns ranging from ductal (Fig 1.5A) 
to sarcomatoid (Fig 1.5B) and solid (Fig 1.5C).  
 
  
 
 
Figure 1.5: Cathepsin B null tumours exhibit decreased proliferation. Tumours in 
cathepsin B null mice exhibit mixed histology with ductal (A), sarcomatoid (B) and 
solid (C) features, similar to KPC tumours. (Scale bar = 200 µm). Proliferation 
measured by phospho-histone H3 is significantly decreased in null tumours compared 
to those that are wild-type for cathepsin B (p=0.0317) (D). Cathepsin B null tumours 
do not exhibit any differences in necrosis (E) or mean vessel density (F) compared to 
KPC tumours.  
42 
 
43 
 
Proliferation in tumours, analysed by phospho-histone H3, revealed that the 
proliferative defect detected in preinvasive lesions was sustained in tumours. At end 
point, tumours in KPC;B-/- mice were significantly less proliferative (50.93 ± 31.20 
phospho-histone H3 index), compared to KPC;B+/+ tumours (66.15 ± 22.61, 
p=0.0317) (Fig 1.5D). There were no significant differences in necrosis between the 
cohorts (Fig 1.5E). In addition, mean vessel density measured by CD31 
immunohistochemistry was not significantly decreased in the KPC;B-/- tumours (Fig 
1.5F).  
Cathepsin B does not alter the stromal composition of diseased pancreata or 
tumours 
The stromal compartment was assessed with Masson’s trichrome stain to evaluate 
collagen deposition and probed with antibodies against alpha-smooth muscle actin to 
delineate activated myofibroblasts. No obvious stromal differences were evident 
between cohorts by either of these parameters. Trichrome staining was abundant in 
diseased areas and tumours irrespective of cathepsin B status (Fig 1.6). In diseased 
pancreata, alpha-smooth muscle actin staining was more robust around areas of 
acinar-ductal metaplasia (arrowheads) than PanINs (arrows) in both KC;B+/+ and   
KC;B-/- mice. There was also no difference in staining pattern in tumours from 
KPC;B+/+ and KPC;B-/- mice (Fig 1.6). This data suggests that the differences in 
cellular proliferation and PanIN content may be cell autonomous. 
 
 Figure 1.6: Cathepsin B loss does not affect stromal composition. Cathepsin B loss 
does not affect the deposition of desmoplastic fibres as measured by trichrome 
staining, in either PanIN pancreas or tumour. Activated fibroblasts, measured by 
alpha-smooth muscle actin are more abundant in areas of acinar-to-ductal metaplasia 
(arrowheads) than PanIN (arrows), irrespective of cathepsin B status. (Scalebar = 
200µm). 
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Cathepsin B loss decreases the burden of liver metastasis 
As cathepsin B has been previously implicated in metastasis (102, 98), a more 
comprehensive examination of the extent of liver and lung metastasis was conducted. 
Liver and lung metastases developed and were histologically similar in KPC;B+/+ 
and KPC;B-/- cohorts  (Fig 1.7A and 1.7B, respectively). KPC;B-/- mice had a 
significant reduction in the number of liver metastases (1.421 ± 2.090), compared to 
KPC;B+/+ mice (4.000 ± 3.882, p=0.0359) (Fig 1.7C). The number of mice with liver 
metastases also decreased from 75% in the KPC;B+/+ cohort to 52.63% in the 
KPC;B-/- cohort, although this difference was not statistically significant (p=0.2928,  
Fisher’s exact test) (Table 1.1). A similar analysis of lung metastases revealed no 
change in metastatic burden (4.563 +/- 1.756 in the KPC;B+/+ cohort; 4.684 +/- 2.033 
in the KPC;B-/- cohort, p=0.6616) (Fig 1.7D). Surprisingly, the incidence of lung 
metastasis increased in the cathepsin B null cohort (78.94%) compared to the 
KPC;B+/+ cohort (62.5%), although this increase was  not significant (p=0.4543) 
(Table 1.1). There was no difference in the area of either liver (Fig 1.7E) or lung (Fig 
1.7F) metastases between cohorts.  
Genotype Number of 
mice 
Mice with 
liver 
metastases 
Incidence 
of liver 
metastasis 
Mice with 
lung 
metastases 
Incidence 
of lung 
metastasis 
KPC;B+/+ 16 12 75% 10 62.5% 
KPC;B-/- 19 10 52.63% 15 78.94% 
Table 1.1: Incidence of liver and lung metastasis 
 Figure 1.7: Decreased liver metastasis due to loss of cathepsin B 
Histology of liver (A) and lung (B) metastases are similar in both cohorts. Although 
cathepsin B is not required for metastasis to the liver, the number of metastases per 
liver is decreased in the null animals (C). There is no significant change in the number 
of metastatic lung lesions (D). Cathepsin B status does not affect the area of either 
liver (E) or lung (F) metastases (Scale bar = 200µm). 
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Cathepsin B loss leads to increased active cathepsin L 
To investigate the difference in metastasis to the liver and lung, the expression of 
alternate cathepsins was examined in metastatic lesions. Cathepsin L was found to be 
higher in lung metastases than in liver metastases in mice in both KPC;B+/+ and 
KPC;B-/- cohorts (Fig 1.8A), potentially indicating a role of this cathepsin in 
metastasis to the lung. 
In addition, an analysis of in vivo cathepsin activity in cathepsin B-null mice 
demonstrated that there was no significant difference in activity compared to B+/+ 
mice in normal and PanIN pancreas and tumours, indicating compensation for 
cathepsin B activity (Fig 1.8B). Western blot analysis of tumour lysates showed that  
KPC;B-/- tumours have more active cathepsin L than KPC;B+/+ tumours (Fig 1.8C, 
arrows). Total ERK is used as a loading control. 
Loss of cathepsin B leads to decreased nuclear phospho-ERK in vivo 
To elucidate the mechanism of decreased proliferation in the cathepsin B null 
background, tumour cell lines were derived from KPC;B-/- mice and transfected with 
recombinant cathepsin B to allow comparison of isogenic cell lines. Evaluation of 
cathepsin B expression in these cell lines (Fig 1.9, lanes 2,4,6) revealed the presence 
of intracellular cathepsin B at levels comparable to KPC;B+/+ cell lines (Fig 1.9, 
lanes 7,8).  Cathepsin B in these reconstituted cell lines was also expressed at the 
plasma membrane and secreted into the medium (Fig 1.9). As expected, there was no 
cathepsin B expression in the parent KPC;B-/- lines (Fig 1.9, lanes 1,2,3). 
 
 Figure 1.8: Cathepsin L expression and activity. Immunohistochemistry for 
cathepsin L shows that the levels of this cathepsin are increased in lung metastases 
compared to liver metastases in both cohorts (A). (Scale bar = 200µm).In vivo 
cathepsin activity does not decrease in cathepsin B null mice in normal, PanIN or 
PDA (B). Cathepsin B null tumours express higher levels of active cathepsin L (C, 
arrows), explaining the lack of diminished cathepsin activity. Total ERK is used as a 
loading control (C).  
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Figure 1.9: Reconstitution of cathepsin B in KPC;B-/- cell lines 
Reconstitution of cathepsin B in null tumour cell lines results in comparable 
expression to tumour cell lines from KPC;B+/+ mice (A, 2,4,6 vs 7,8). As expected, 
cathepsin B is absent in the null cell lines (A, lanes 1,3,5). After reconstitution, 
recombinant cathepsin B is expressed on the plasma membrane in its active form. 
Inactive cathepsin B is secreted into the medium (A, 2,4,6).  
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Figure 1.10: Cathepsin B loss does not affect interleukin-6 levels. Interleukin-6 
ELISAs on tumour tissue reveals that cathepsin B loss does not affect IL-6 levels (A). 
Stat3 phosphorylation is not decreased in the cathepsin B null background (B). This 
data is consistent in cell lines, where reintroduction of cathepsin B into null cell lines 
does not affect IL-6 levels (C) or Stat3 phosphorylation (D 1vs2, 3vs4, and 5vs6). 
Total ERK is used as a loading control.  
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Since cathepsin B is known to be involved in the cleavage and processing of a number 
of cytokines and chemokines (108-110), antibody-based cytokine arrays were utilized to 
enumerate the differences in cytokine levels between KPC;B+/+ and KPC;B-/- 
tumours (Appendix 1). The protein which demonstrated the highest reduction was 
interleukin-6, a cytokine that is of interest in human PDA (111). To confirm whether 
interleukin-6 is indeed down-regulated in a cathepsin B null background, ELISAs 
were carried out on tissue lysates from the same tumours used for the array analysis.  
The interleukin-6 ELISA showed that there was overall no difference between the 
tumours from the two cohorts, and only one outlying KPC;B+/+ sample with high 
expression levels was responsible for the array results (Fig 1.10A). Western blotting 
for Stat3, a known transducer of interleukin-6 signalling, confirmed that this pathway 
is not less active in KPC;B-/- tumours (Fig 1.10B). The interleukin-6 ELISA was also 
carried out on the cell lines reconstituted with cathepsin B and confirmed that there 
was no difference in interleukin-6 levels (Fig 1.10C) or Stat signalling (Fig 1.10D, 
lanes 1vs2, 3vs4 and 5vs6) in cell lines expressing cathepsin B. Total ERK is used as 
a loading control. 
The cell lines were then analyzed for a number of signalling molecules and targets of 
the Ras pathway. No changes were seen in levels of phospho-Akt, phospho-Rsk, 
phospho-S6 ribosomal protein and cyclin D (Fig 1.11A, lanes 1vs2, 3vs4 and 5vs6). 
Cathepsin B expression, however, caused increased levels of phospho-ERK (Fig 
1.11A, 1vs2, 3vs4 and 5vs6) in all three cell lines. To further investigate this finding, 
phospho-ERK immunohistochemistry was conducted on PanIN lesions from 
KC;B+/+ and KC;B-/- mice. Although the overall intensity of cytoplasmic phospho-  
 
 
Figure 1.11: Cathepsin B affects phospho-ERK localization in vivo. Western 
blotting of cancer cell lines shows that cathepsin B expression leads to the 
upregulation of phospho-ERK in cancer cell lines (A, 1vs2, 3vs4, 5vs6). Phospho-
ERK levels quantified by densitometry have been normalized to total ERK. Cathepsin 
B does not affect activation of other signalling molecules downstream of Ras 
including Akt, Rsk, S6 ribosomal protein and does not increase cyclin D1 levels (A). 
Localization of phospho-ERK in KC;B-/- PanINs was altered with a significant 
reduction in the number of phospho-ERK positive nuclei compared to KC;B+/+ 
PanINs (p=0.0025) (B, arrows). (Scale bar = 50µm).  
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ERK staining did not vary between the cohorts, differences in nuclear positivity were 
observed. PanIN lesions in KC;B+/+ pancreata exhibited a significantly higher 
percentage of phospho-ERK positive nuclei (93.48% +/- 1.787%) compared to KC;B-
/- pancreata (62.26% +/- 8.740) (p=0.0025) (Fig 1.11B).  
Modulation of phospho-ERK is not a result of altered MAP kinase signalling 
Analysis of the cell lines revealed that the cathepsin B-induced increase in phospho-
ERK was not due to Ras activation, as there was no consistent difference in Ras-GTP 
or phospho-MEK. There were no changes in phosphatases known to regulate MAP 
kinase signalling such as MKP1, MKP2, MKP3 and Sprouty2 (Fig 1.12A, 1vs2, 3vs4, 
5vs6). Additionally, surface biotinylation of cell lines followed by neutravidin pull-
down showed that there was no difference in levels of cell surface receptors such as 
Her2, EGFR, cKit and PDGFRα (Fig 1.12B, 1vs2, 3vs4 and 5vs6), further 
corroborating that the altered phospho-ERK was not simply due to modulation of 
MAP kinase signalling. Total ERK is used as an input control (Fig 1.12B). 
Cathepsin B expression results in increased growth in soft agar 
To evaluate the role of Cathepsin B expression in vitro, proliferation assays were 
conducted at 10% serum and 1% serum on plastic. Interestingly, there was no 
difference in proliferation at either condition (Fig 1.13A). Two of the cell lines with 
higher cathepsin B and phospho-ERK levels were selected for further studies. In soft 
agar assays, the cathepsin B-expressing cell lines formed larger colonies than lines 
lacking cathepsin B (Fig 1.13B).  
 
 Figure 1.12: Increased phospho-ERK is not due to altered MAP kinase 
signalling. Cathepsin B expression does not affect levels of Ras-GTP or phospho-
MEK. In addition, there are no changes in levels of phosphatases MKP1, MKP2, 
MKP3 and sprouty2 that are involved in modulation of MAP kinase signalling (A, 
lanes 1vs2, 3vs4, and 5vs6). Surface biotinylation of cancer cells reveals that levels of 
Her2, EGFR, cKit and PDGFRα are not altered at the plasma membrane (B). Total 
ERK is used as the input control (B). 
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Figure 1.13: Cathepsin B increases colony growth in soft agar assays. Cathepsin B 
is not required for proliferation of adherent cells at either 10% or 1% serum (A). 
Representative images from two cell lines show that cathepsin B expression results in 
increased growth in soft agar assays (B). 
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Cathepsin B expression increases growth of subcutaneous allografts  
To examine the role of cathepsin B on proliferation in vivo, and also to investigate 
whether cathepsin B has cell autonomous or non-cell autonomous roles in tumour 
growth, the cell lines were injected subcutaneously into wild-type (C57Bl6)  and 
cathepsin B null mice to  produce allografts. .  
Cathepsin B-transfected cells formed larger tumours in both wild-type (0.2591 cm3 +/- 
0.165, p=0.0007) and cathepsin B null recipient mice (0.2432 cm3 +/- 0.094, 
p=0.0041) compared to their null counterparts (0.09069 cm3 +/- 0.081 in wild-type 
mice and 0.1300 cm3 +/- 0.0779 in cathepsin B null mice) (Fig 1.14A, B). Analysis of 
proliferation by Ki67 showed that allografts formed by cathepsin B-expressing 
tumours have significantly increased proliferation in both backgrounds compared to 
tumours that lack cathepsin B expression (Fig 1.14C).  
E64 in combination with gemcitabine does not improve survival compared to 
gemcitabine therapy  
To investigate whether cathepsin B is a potential therapeutic target in PDA, the broad-
spectrum cysteine protease inhibitor E64 was used as a therapeutic agent in mice 
bearing pancreatic tumours. E64 (50mgs/kg) was given daily to tumour-bearing mice 
intraperitoneally, either as a single agent or in combination with bi-weekly 
gemcitabine (100mgs/kg) till endpoint. The median survival on study of mice 
receiving E64 alone was 14 days, compared to 23 days for the combination arm (Fig 
1.15A). As has been reported previously in this system, the median survival for 
untreated mice is 11 days, and 15 days for Gemcitabine alone (Fig 1.15B) (43). 
  
 
 
Figure 1.14: Lack of cathepsin B inhibits the growth of subcutaneous allografts. 
Tumour cells expressing cathepsin B (right flank) form larger subcutaneous tumours 
than cells lacking cathepsin B (left flank) in both wild-type and cathepsin B null 
recipient mice  (A), with tumour volume at end point being significantly increased 
(B). This increased tumour size corresponds to increased proliferation as measured by 
the number of Ki67 positive cells per field (C).  
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Figure 1.15: E64 in combination with Gemcitabine leads to a significant increase 
in survival. The median survival of mice receiving E64 in combination with 
gemcitabine is 23 days, a significant increase over E64 as a single agent (14 days) 
(A). Previously published data are provided as a reference for vehicle (11 days) and 
Gemcitabine (15 days) (B) (43) 
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The historical vehicle and gemcitabine control cohorts serve as a reference, as similar 
additional cohorts have been completed that corroborate the accuracy of the data 
(Tuveson, unpublished).  Although E64 alone did not impart a survival benefit, the 
combination of E64 and gemcitabine provided a significant increase in survival 
compared to vehicle (p=0.0137) or E64 alone (0.0271). The combination treatment 
extended median survival on treatment by 53% compared to Gemcitabine alone, 
although this is not statistically significant (p=0.1541). This may be a result of 
augmentation of gemcitabine delivery to tumours, which remains to be investigated. 
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DISCUSSION 
The cysteine cathepsin family of lysosomal proteases is of great interest due to their 
overexpression and mislocalization in a number of cancers (reviewed in 58). In pancreatic 
cancer in particular, cathepsin B has been reported to be overexpressed in primary 
tumours  and associated metastases in humans (112). In addition, cathepsin B is also of 
interest in human PDA as a prognostic indicator of early recurrence after surgical 
resection (77, 113).  
Following the initial observation that cathepsin B levels and overall cathepsin activity 
are increased in preinvasive and invasive pancreatic cancer in mice, and that mouse 
PDA cell lines have altered cathepsin B localization, this work delves into the role of 
cathepsin B in the initiation and progression of PDA. I have shown that cathepsin B 
loss causes a significant decrease in PanIN burden at an early time point, as well as 
sustained decreased proliferation in PanINs at early and late time points. In addition, 
loss of cathepsin B confers a significant survival advantage to mice with PDA in two 
accelerated models of pancreatic cancer. In both of the accelerated models, loss of 
cathepsin B delays onset of PDA. The survival benefit imparted by lack of cathepsin 
B is associated with decreased tumour proliferation, although the stromal and vascular 
compartments are not affected. Cathepsin B loss also corroborates with decreased 
liver metastases, and increased cathepsin L activity in tumours (Fig 1.16). 
The observation that early morbidity is absent in cathepsin B null mice indicates that 
tumour development is retarded in the absence of cathepsin B. A major characteristic 
of PDA is the profound deposition of extracellular matrix consisting of numerous  
  
 
 
Figure 1.16: Schematic of cathepsin B involvement in the tumorigenic process. 
Cathepsin B may promote the progression from preinvasive disease to frank 
carcinoma by degrading extracellular matrix components. Cathepsin B influences 
proliferation and therefore promotes tumour progression. Although cathepsin B is not 
required for metastasis to the liver, establishment of metastatic lesions in the liver is 
more efficient in the presence of this protease. Cathepsin L is upregulated in lung 
metastases, and may therefore be important in site-specific metastasis to the lung. 
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components including collagens, laminin and fibronectin (reviewed in 22, 23). The 
significance of cathepsin B in this setting is its ability to cleave collagen IV, laminin  
and fibronectin, as has been reported in normal and tumour tissue (114). In addition, 
mislocalization of cathepsin B to the plasma membrane is reported to be induced by 
Ras oncogenes (91, 115, 116). This may reflect the importance of cathepsin B in the 
degradation of the extracellular matrix and the progression from ductal carcinoma in 
situ to frank cancer, a highly probable scenario given that mouse PDA cell lines 
express active cathepsin B on their plasma membrane. Cathepsin B under cell culture 
conditions is secreted into medium as its inactive precursor, a phenotype that has been 
previously reported in other cell culture systems (53, 117). Given that acidic 
extracellular pH is a common feature of tumours (reviewed in 118, 119), it is easy to envision 
a situation where the inactive cathepsin B is activated due to the extracellular milieu. 
Indeed, incubating culture medium with pepsin at acidic pH is sufficient to activate 
secreted procathepsin B (117, 90). In this scenario, activation of cathepsin B may also be 
involved in promoting metastasis. Interestingly, active cathepsin B can also be 
secreted  from cancer cells in response to acidic extracellular pH (93), and metastasis is 
promoted by low pH  (120). 
In our system, cathepsin B loss significantly decreases the burden of liver metastasis, 
with no change in metastatic burden in the lungs. In addition, there appears to be a 
trend towards decreased incidence of metastasis to the liver and, unexpectedly, 
increased evidence of metastasis to the lung. The finding that cathepsin L expression 
is increased in lung metastases compared to liver metastases suggests that different 
cathepsins may be responsible for site-specific metastasis. Interestingly, tissue from 
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cathepsin B null mice does not exhibit decreased in vivo cathepsin activity. This is 
explained by the presence of increased levels of active cathepsin L in the cathepsin B 
null tumours, which may account for the successful establishment of lung metastases. 
This is supported by evidence suggesting that proteases with different substrate 
specificities may variably affect metastasis to different distal sites (121, 122). Moreover, 
crossing cathepsin B knockout mice into the MMTV-PyMT model of metastasizing 
breast cancer did not result in significantly reduced lung metastatic burden (102). In this 
model, an alternate cystein cathepsin, cathepsin Z, partially compensates for the loss 
of cathepsin B (102). Indeed cathepsin B/Z double knockouts show significantly 
reduced lung metastasis of the breast cancers (123). Hence cathepsin B is part of a 
proteolytic network that affects metastasis. 
The effect of cathepsin B loss on proliferation has been previously reported in vivo in 
other mouse models of cancer (97, 100). Although the mechanism by which cathepsin B 
affects proliferation is not well understood, recently some mechanistic insight has 
been gained in vitro in cancer cell lines, albeit primarily in studies studying the 
cooperative effect of inhibition or silencing of multiple proteins. Concomitant knock-
down of cathepsin B with the urokinase plasminogen activator receptor in glioma cell 
lines results in increased p27 expression and G0/G1 cell cycle arrest (124), and 
decreased phosphorylation of focal adhesion kinase and ERK (125) . Silencing of 
cathepsin B together with either matrix metalloprotease-9 or uPAR reduces colony 
growth and proliferation in glioma cells, in this case through integrin downregulation 
(126).  In hepatic stellate cells, inhibition of cathepsin B led to decreased Akt 
phosphorylation and an associated reduction in proliferation in response to platelet-
derived growth factor (127). Given that proliferation is consistently decreased at both 
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early and late stages of disease in our model in the setting of cathepsin B loss, this is a 
potential mechanism to explain the delayed tumour progression in these mice. This 
defect in proliferation does not appear to be a result of altered interleukin signalling in 
tumours and cell lines. The effect of cathepsin B loss on phospho-ERK both in vitro 
and in vivo is striking, and may explain the defect in proliferation. Although, 
cathepsin B inhibition has been previously reported to affect phosphorylation of 
various signalling molecules with corresponding decreases in proliferation (125, 127), 
this study is the first to report that cathepsin B affects the localization of phospho-
ERK. The nuclear localization of phospho-ERK leads to the activation of transcription 
factors responsible for proliferation, and hence sequestration in the cytoplasm may 
prevent responses to mitogenic stimuli (reviewed in 128).  
Since cathepsin B is expressed in both tumour and stromal cells, it may have non-cell 
autonomous roles as a result of paracrine signals between the different cell types. This 
conclusion is consistent with the finding that intravenous injection of cathepsin B 
expressing tumour cells into cathepsin B null mice results in lung metastases with 
decreased proliferation (100). Recent supporting cell culture evidence has been reported 
where the use of cathepsin B-specific inhibitors has led to decreased proliferation of 
endothelial cells (129).The allograft experiments presented here strongly support a cell-
autonomous role of cathepsin B in PDA, as cell lines expressing the protease 
proliferate more rapidly than cathepsin B-null cell lines irrespective of the 
background into which they are injected. The relative contributions of intracellular 
and extracellular cathepsin B in this setting remain to be clarified. These experiments 
do not exclude an additional non-cell autonomous role for cathepsin B, as the stromal 
response in allografts is rather limited compared to that seen in in situ tumours.  
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Cathepsins are under investigation as therapeutic targets in cancer. Previous studies 
conducted in vivo have shown promise in conjunction with chemotherapy (130), 
although bioavailability of the inhibitor may be problematic in specific cancer types 
(131). In this system, inhibition of extracellular cathepsin B using a broad-spectrum 
cysteine protease inhibitor leads to an increase in survival when combined with 
gemcitabine, compared to treatment with the inhibitor alone. Although the improved 
survival in combination treatment was not statistically significant compared to 
Gemcitabine alone, the drug used here was not an optimal cathepsin inhibitor and the 
positive trend underlines the importance of understanding the specific contributions of 
different cathepsins in cancer. This work validates cathepsin B as a potential 
therapeutic target in pancreatic cancer, although caution must be exercised due to the 
successful establishment of lung metastases in the absence of cathepsin B. In this 
context, the use of a broad-spectrum cathepsin inhibitor may be more beneficial than 
targeting a single cathepsin enzyme. 
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CONCLUSIONS/FUTURE DIRECTIONS 
In summary, cathepsin B is involved in the initiation and progression of pancreatic 
cancer, and loss of this protease provides a significant survival benefit. Cathepsin B 
loss results in decreased proliferation and metastasis to the liver, although cathepsin L 
activity is increased potentially permitting successful lung metastasis. Cathepsin B 
deficiency results in decreased phosphorylated ERK in cell lines, and decreased 
nuclear localization of phospho-ERK in vivo. Cathepsin B restoration improves 
anchorage-independent growth and growth of subcutaneous allografts in a cell 
autonomous manner.  
Pancreatitis 
Pancreatitis originates in the acinar cell compartment of the pancreas, and involves 
the intracellular activation of trypsinogen to active trypsin (reviewed in 132). Cathepsin B 
can activate trypsinogen in vitro(133), and induced pancreatitis in mouse models results 
in the redistribution of cathepsin B in zymogen granule-containing sub-cellular 
fractions (134). Importantly, cathepsin B null mice exhibit decrease trypsinogen 
activation and pancreatic damage in response to induced pancreatitis (105). Since 
pancreatitis is a risk factor for pancreatic cancer, the importance of cathepsin B in 
induction of pancreatitis must be investigated, using the KC;B-/- mice. Induction of 
pancreatitis using established methods (135) in these mice will allow the examination of 
whether cathepsin B loss in the presence of oncogenic Kras mutations affects the 
course of disease. In addition, these experiments may address the question of whether 
progress from pancreatitis to preinvasive and ductal carcinoma is affected by the lack 
of cathepsin B.  
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Non-cell autonomous contribution of cathepsin B 
The growth of cathepsin B-expressing tumour cells in allografts presented in this 
work supports a cell autonomous role for cathepsin B in pancreatic cancer. It does not, 
however, rule out any non-cell autonomous functions and these must be investigated 
in order to understand the various mechanisms by which cathepsin B affects 
tumorigenesis. Furthermore, cathepsin B from tumour-associated macrophages is 
known to promote tumour growth, angiogenesis and invasion in vivo (103). The non 
cell autonomous effects of cathepsin B in pancreatic cancer tumorigenesis could be 
studied by bone marrow transplants to introduce cathepsin B null immune cells into 
KC;B+/+ mice, or alternately to reconstitute the immune system of KC;B-/- mice with 
cathepsin B-expressing cells. In addition, the effects of extracellular cathepsin B and 
its contribution to proliferation and metastasis can be studied in vitro and in vivo using 
non-cell permeable cathepsin B-specific inhibitors such as Ca074. 
Cathepsin B and the localization of phospho-ERK  
The finding that phospho-ERK localization is affected in cathepsin B null PanINs is 
an interesting observation, the mechanism for which remains to be elucidated. 
Nuclear phospho-ERK is required for proliferation (reviewed in 128), which can be affected 
by numerous signals. For instance, integrin-mediated adhesion and the resulting 
cytoskeletal organization are required for the nuclear translocation of ERK (136). Other 
mechanisms regulating ERK nuclear localization are src kinase and Rho/ROCK 
activation, the importin machinery and Pea-15 (137-139). Cathepsin B silencing results 
in downregulation of a number of integrins (126), and simultaneous downregulation of 
uPAR and cathepsin B modifies cytoskeletal dynamics by retarding cofilin 
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dephosphorylation (125). Thus, cathepsin B loss might affect phospho-ERK 
localization by inhibiting integrin expression or altering cytoskeletal reorganization, 
directly and indirectly. Cathepsin B null cancer cell lines and MEFs can be used to 
explore alterations in integrin expression, and their relationship to nuclear phospho-
ERK.  
Cathepsins in metastasis  
I have shown that cathepsin B loss diminishes the ability of tumour cells to 
metastasize to the liver, but has no impact on lung metastasis. Lung metastases 
express higher levels of cathepsin L than do liver metastases. In addition, cathepsin B 
null tumours tend to have higher levels of active cathepsin L. This data may indicate 
the importance of compensatory networks of protease activity, which has been 
previously shown in mouse models (123). In order to study the contribution of 
cathepsin L to metastasis in a cathepsin B null background, short hairpin knockdown 
of cathepsin L may be carried out in tumour cell lines, followed by injection into 
cathepsin L null recipient mice, either by an intravenous or intrasplenic route. In 
addition, since cathepsin Z is thought to compensate for cathepsin B loss, this 
protease must also be analyzed in the cathepsin B null models of pancreatic 
carcinogenesis. Studying other cathepsins in this manner will not only delineate the 
functions of proteases in metastasis, but will also give a clearer indication of how 
cathepsin B loss is compensated for in tumours, which may explain why the absence 
of cathepsin B in PDA models does not have a greater impact on tumorigenesis. 
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FARNESYLTHIOSALICYLIC ACID AS A THERAPEUTIC 
AGENT IN PANCREATIC CANCER 
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INTRODUCTION 
 
The Ras proteins 
The first Ras proteins were identified in 1964 by Jennifer Harvey (H-Ras) and in 1970 
by Werner Kirsten (K-Ras) from transforming retroviruses carrying host oncogenes 
that produced tumours in mice (140, 141). Following this discovery, the human 
homologues of these oncogenes were identified in 1982, and the third Ras protein (N-
Ras) was identified from neuroblastoma cells in 1983 (142-145).  
The Ras proteins are small, ubiquitously-expressed guanosine nucleotide-bound 
GTPases. Ras proteins cycle between an inactive GDP-bound form and an active 
GTP-bound form. They are activated by multiple upstream signals including the 
binding of growth factors to receptors, G-protein signalling, activation of Janus 
kinases and calcium signalling (Fig I2.1).  Activation through receptor tyrosine 
kinases results in the interaction of the adaptor protein Grb2 with the cytoplasmic tail 
of the receptor, thereby facilitating son-of-sevenless (SOS) recruitment to the 
membrane. SOS proteins are guanosine nucleotide exchange factors (GEFs) that 
activate Ras proteins by increasing the exchange of GDP for GTP (reviewed in 146-149).  
Active GTP-bound Ras is a central signalling hub within the cell and activates a 
number of downstream pathways, and controls various aspects of cellular behaviour 
including proliferation, survival and cytoskeletal reorganization. The most intensively 
studied pathway downstream of ras is the mitogen-activated protein kinase (MAPK) 
pathway. Active ras contributes to the activation of Raf protein, downstream of which 
lie MEK and the extracellular signal-related kinases (ERKs). The phosphorylation of 
ERK results in the activation of the AP-1 transcription factor, comprising Jun and Fos  
  
 
Fig I2.1 Ras signalling cascades. Ras is activated in response to upstream signals 
through numerous mechanisms such as receptor tyrosine kinases, G protein coupled 
receptors, Janus Kinases and calcium. Oncogenic Ras is intrinsically active and does 
not require these signals. Ras signals to numerous downstream pathways, three of 
which are represented in this image. Ras signalling stimulates processes such as 
proliferation, protein synthesis, survival and cytoskeletal reorganization.   
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heterodimers, which causes expression of cell-cycle regulatory proteins including the 
D-type cyclins (reviewed in 150, 151).  
In addition to MAPK signalling, Ras also activates a number of other effector 
pathways. Ras directly interacts with type I phosphatidylinositol 3-kinases (PI3Ks), 
resulting in their activation and phosphorylation of downstream targets Akt and 
PDK1, with resulting effects on survival and protein synthesis respectively. Ras 
signalling also impinges upon cytoskeletal reorganization and through its activation of 
the Ras guanine nucleotide dissociation stimulator (RalGDS), and the subsequent 
activation of Cdc42 (Fig I2.1). Other ras effectors include phospholipase Cε and 
Rassf1 (reviewed in 152).  
Although the three Ras proteins are closely related, with 85% amino acid sequence 
homology, and their functionality and effects in vitro are very similar, mouse models 
have delineated differences in their functions in vivo. H-Ras and N-Ras proteins are 
not required for normal mouse embryonic development, either alone or in 
combination (153, 154). H-Ras deficiency however, results in impaired skin tumour 
formation in response to carcinogens and N-Ras deficient mice exhibit defective T-
cell function and immune responses (155, 156). K-ras, in contrast, is essential for 
embryonic development and knockout mice experience defective liver erythropoiesis 
and anaemia leading to gestational death (157), although this has been attributed to the 
Kras4B isoform, as Kras4A is not required for normal mouse development (158). This 
data suggests that Ras proteins have certain non-overlapping functions and K-Ras 
deficiency in mouse tissues cannot be compensated. 
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Ras mutations in cancer 
Ras mutations are the most frequent oncogenic event identified in cancer, with an 
overall frequency of about 30%. Of the ras proteins, K-ras is the most frequently 
mutated, being found in >90% of ductal pancreatic cancers, 45% of colorectal cancers  
and 35% of non-small cell lung cancers (152). The mutations, mostly confined to 
codons 12, 13 and 61, decrease the intrinsic GTPase activity and result in 
hyperactivation of the protein and aberrant downstream signalling, and do not require 
upstream signals (143, 159, 160). Ras mutations in cancer are associated with poor 
prognosis and outcome. Augmentation of ras signalling in cancer also occurs by other 
mechanisms such as by deletion of GAPs, mutational activation of growth factor 
receptors, and mutation or amplification of individual ras effectors (152).  
Oncogene addiction 
Oncogene addiction, a phrase coined by Bernard Weinstein, refers to the 
characteristic whereby cancer cells appear to be dependent on a single oncogenic 
event or signalling pathway to maintain their proliferation and survival, despite 
numerous other genetic alterations (161). Experimental findings in human cell lines and 
mouse cancer models provide support for this phenomenon. Tumour dependency on 
oncogenes such as myc and ras has been well-studied, but experimental systems have 
also been used to demonstrate dependence upon other genes such as  her2, Braf, 
EGFR, Met and Abl, as well as micro RNAs(reviewed in 162). Oncogene addiction implies 
a cell autonomous response to oncogene inactivation. The genetic streamlining 
hypothesis proposes that natural selection and the inherent genomic instability in 
tumour cells results in the rewiring of signalling pathways with preference given to 
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oncogenic signalling.  The benefit of this tumour characteristic is the relative 
insensitivity of normal tissues to the inactivation of oncogenes, making therapeutic 
approaches feasible without the overwhelming side effects often engendered by 
general chemotherapeutics (reviewed in 162). 
Targeting ras in cancer 
 The localization of ras to the plasma membrane is essential for its activity, and 
therefore an obvious target for therapy was the post-translational modifications 
responsible for ras localization. Newly synthesized cytosolic ras is modified on its 
carboxyl terminus CAAX motif, where A is an aliphatic or aromatic residue and X is 
the terminal amino acid determining the specificity of the prenyl transferase. Farnesyl 
transferase (FTase) catalyses the addition of a 15-carbon isoprenoid chain from 
farnesyl pyrophosphate (FPP) onto the cysteine residue. This is followed by the 
release of the AAX residues, which is catalysed by ras converting enzyme (RCE1) by 
endoproteolytic digest. Finally, isoprenylcysteine carboxy methyl transferase (ICMT) 
methylates the isoprenylcysteine and this fully processed ras associates with the 
membrane. (Fig  I2.2) (reviewed in 163).  
Several strategies have been employed to inhibit ras farnesylation, the most common 
being the design of CAAX peptidomimetics that compete for binding to FTase and 
are therefore potent and selective inhibitors of FTase. A large number of 
farnesyltransferase inhibitors (FTIs) have been developed as potential anti-cancer 
therapies through high-throughput screening methodologies (164, 165). These were 
shown to effectively inhibit Hras in cell culture. Evidence from mouse models also 
supported the use of FTIs in cancer therapy. In MMTV-Hras mice, for instance,  
  
Fig I2.2 Processing of Ras proteins. Ras proteins undergo modifications with 
isoprenyl groups on their CAAX motif. Farnesyl transferase is responsible for the 
farnesylation of the CAAX motif, followed by the excision of –AAX by RCE1. ICMT 
then methylates the C- residue, and fully processed ras is able to associate with the 
membrane. Kras and Nras can undergo an alternate modification in the absence of 
farnesylation. Geranyl geranyl transferase is responsible for the addition of geranyl 
geranyl groups to the CAAX motif.  
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mammary carcinomas were efficiently reversed by FTI with very little associated 
toxicity (166). Xenograft tumours of Calu-1 human lung adenocarcinoma responded 
well to FTIs, where tumour growth was blocked (167, 168). Efficacy was also seen 
against intracranial glioblastoma in nude mice and in chemically-induced lung cancer 
mouse model (169-172).   
The initial expectations for FTIs in cancer therapy were unfortunately not realized. 
The mechanism of action of FTIs remains unclear, and the successes seen in mouse 
models has not been recapitulated in human clinical trials. The main cause for this is 
that Kras, and to some extent Nras, can be alternatively prenylated. This prenylation is  
catalyzed by geranylgeranyl transferase I (GGTI), which uses geranylgeranyl 
pyrophosphate (GPP) as a substrate to add a 20-carbon geranylgeranyl group to the  
cysteine residue (Fig I2.2). Geranylgeranylation of Kras is only important under 
circumstances when farnesylation is blocked, and provides an alternate pathway for 
membrane localization, thus bypassing the inhibition of FTase. Attempts to inhibit 
Kras function by combining FTIs and GGTIs have been unsuccessful due to excessive 
toxicity associated with the combination (173).  
Farnesylthiosalicylic acid  
Ras membrane localization is mediated by interactions between the farnesyl moiety of 
ras and prenyl-binding pockets in proteins such as galectin-1 and galectin-3 (174, 175), 
which provides new possibilities for targeting ras. Farnesylthiosalicylic acid (FTS) is 
a small molecule rigid carboxylic acid derivative that mimics the farnesylated moiety 
of Ras (Fig I2.3A) (176). Unlike the FTIs, FTS does not interfere with ras processing, 
rather it prevents the localization of fully-processed ras to the membrane by inhibiting 
  
 
 
Fig I2.3 Mechanism of action of FTS. FTS is a small molecule mimetic of farnesyl 
groups (A). Active ras anchors to the membrane through proteins such as Galectins. 
Membrane-anchored ras is able to activate signalling cascades. FTS competes with 
Ras for galectin binding sites, thereby inhibiting the activation of downstream signals.  
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its interactions with galectin (174, 175, 177, 178). It is readily taken up by cells, and appears 
to disrupt the association of ras with the cell membrane and to selectively inhibit ras- 
dependent cell growth (177, 178). Treatment of ras-transformed rodent fibroblasts 
resulted in downregulation of MAP kinase signalling (179). Glioblastoma cells treated 
with FTS exhibited decreased PI3kinase signalling and subsequent inhibition of cell 
migration by altering the rac-rho balance in the cells, and decreased hypoxia-inducible  
factor-1 alpha causing cessation of glycolysis and cell death (180, 181).  In 
neuroblastoma cell lines, the use of FTS resulted in attenuated MAPK and PI3K 
signalling, loss of MycN and inhibition of cell growth (182). Experiments in xenograft 
models have supported the use of FTS as a therapeutic agent. The growth of ras-
transformed rat-1 cells is inhibited by FTS in nude mice (183). Panc-1 pancreatic cancer 
cells and melanoma cells carrying ras mutations both responded to FTS therapy (184-
186).  
FTS is also being tested in clinical trials in human patients. A first-in-man phase I 
clinical study indicated that FTS is well-tolerated in patients with solid tumours, and 
29% of patients exhibited stable disease on treatment of >= 4 months, with a range of 
4-23 months (187). It is currently in trials for a number of different cancer types 
including non-small cell lung cancer, pancreatic and biliary tumours and solid and 
hematologic tumours. 
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MATERIALS AND METHODS 
Mouse strains 
The LSL-KrasG12D, LSL-Trp53R172H and Pdx-1-Cre strains of mice have been 
previously described (27, 28). These strains of mice were interbred to ensure a mixed 
C57BL6/129Sv background for survival studies. Mice were housed and maintained, 
and experiments were conducted, in compliance with UK home office regulations.  
Generation of experimental animals 
LSL-KrasG12D; Trp53R172H; Pdx-1-Cre: LSL-KrasG12D; Trp53R172H mice were bred to 
Pdx-1-cre mice to generate KPC tumour mice used for survival and short-term 
studies. 
Reagents 
S-trans,trans-Farnesylthiosalicylic acid (FTS) was obtained from Concordia 
pharmaceuticals. Gemzar powder, produced by Eli Lilly was purchased. 
Carboxymethyl cellulose (CMC) was obtained from Sigma Aldrich. Alexa Fluor 
conjugated secondary antibodies for co-immunofluorescence were obtained from 
Invitrogen.  
Imaging of pancreatic tumours 
High resolution ultrasound (US) imaging of mice was carried out to identify and 
quantify pancreatic tumours, as described previously (43, 188). Mice were anesthetized 
with isofluorane and the long hair was then shaved, followed by depilation using 
cream to remove any remaining hair. 3-4 mls of sterile saline was injected 
intraperitoneally to improve contrast. Imaging was performed using the Vevo770 
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system (Visual Sonics) with a 35MHz RMV Scan head. Three dimensional images for 
quantification of tumour volume were obtained by collecting serial images at 0.25mm 
intervals. Tumour reconstruction was carried out using Vevo 770 software by 
manually outlining the tumour in each 2-dimensional frame.  
Study structure 
KPC mice were enrolled on study when tumours measured 6-9 mm mean diameter by 
ultrasound. Mice enrolled on survival studies were imaged bi-weekly till endpoint. 
Mice enrolled on short-term studies did not receive further ultrasounds after 
enrolment. Endpoint is defined by a number of criteria including development of 
ascites, weight loss > 20%, severe cachexia or other obvious signs of ill health 
including extreme inactivity.  
All studies included four treatment groups – vehicle, gemcitabine, FTS alone and FTS 
in combination with gemcitabine. Vehicle-treated mice were administered 
carboxymethylcellullose (CMC) daily by oral gavage. Mice on the gemcitabine arm 
received CMC daily and bi-weekly intraperitoneal injections of 100mg/kg 
gemcitabine. FTS was administered daily by oral gavage at 100mg/kg.  
Drug formulation 
The vehicle used for formulation of FTS is carboxymethyl cellulose (CMC). 0.5% 
CMC was prepared as previously described (189). 0.5 gms CMC was dissolved in 
50mls sterile water by stirring for approximately 4 hours, following which the 
solution was brought up to 100mls.  
FTS was formulated at a concentration of 10mgs/ml by grinding in a mortar and 
pestle. CMC was gradually added, with constant grinding, to form a milky 
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suspension. The solution was poured out of the mortar and pestle, and they were 
rinsed with CMC to extract any remaining FTS. FTS in this preparation is stable at 
4°C for a month. Before administration, the drug was brought to room temperature 
along with constant stirring to resuspend any settled drug.  
Gemcitabine stock of 5mg/ml was prepared by dissolving Gemzar (48% difluoro-
deoxycytidine) in sterile normal saline. Gemcitabine goes into solution rapidly and 
was prepared fresh immediately before use every time.  
Immunohistochemistry 
Immunohistochemistry was carried out on tissue using the same protocol as described 
in chapter I. The antibodies used were phospho-histone H3, alpha smooth muscle 
actin, Ki67 and phospho-ERK that are listed in table M1.1 
Co-immunofluroescence 
Tissue sections were deparaffinised in xylene and rehydrated through a graded 
alcohol series into 1X PBS as for immunohistochemistry. Antigen retrieval was 
mediated by boiling 10mM citrate buffer, pH6.0 and the slides were cooled. Slides 
were blocked with 10% serum + 1% BSA in TBST for 1 hour at room temperature. 
Slides were then incubated overnight at 4°C with a mixture of 1:100 diluted Ki67 
antibody (Neomarkers) and 1:100 dilution of alpha smooth muscle actin antibody 
(Abcam). Sections were washed with TBST and were incubated with 1:500 dilutions 
of the relevant alexa fluor conjugated secondary antibodies at room temperature for 
one hour. The slides were then washed with TBST and mounted in Prolong gold anti-
fade reagent with DAPI (Invitrogen). Slides were imaged using the Nikon Eclipse 90i 
microscope with the D-Eclipse C1 Si confocal system. 
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FTS pharmacokinetic analysis  
Plasma samples for FTS pharmacology were obtained as follows – blood was 
collected by terminal cardiac puncture into tubes containing lithium-heparin. Samples 
were spun at 6000g for 10 minutes, plasma was aliquoted and snap frozen in liquid 
nitrogen. Tissue samples were snap frozen in liquid nitrogen.  
The protocol for FTS pharmacokinetic analysis has been previously published (190). 
Prior to extraction, frozen samples were thawed in a water bath at ambient 
temperature.  Tissue homogenates were prepared at a concentration of 200 mg/mL in 
PBS and further diluted 1:5 or 1:10 in human plasma prior to extraction.  Mouse 
plasma was diluted 1:10 in human plasma prior to extraction.  Sample preparation 
involved a liquid-liquid extraction by the addition of 0.5 mL of plasma or tissue 
homogenate with 5 mL of methyl t-butyl ether containing 20 ng/mL of the internal 
standard S-trans,trans-5-fluoro-farnesylthiosalicylic acid (5-F-FTS).  
Chromatographic separation was achieved on a Waters X-Terra C(18) (50 mm x 2.1 
mm i.d., 3.5 µm) analytical column using a mobile phase consisting of acetonitrile 
containing formic acid (0.1%, v/v)/ammonium acetate (10 mM) (80:20, v/v) using 
isocratic flow at 0.2 mL/min for 5 minutes. FTS and the internal standard were 
monitored by a Micromass Quattro LC triple-quadrupole MS detector using an 
electrospray probe operating in negative ionization mode.  Linear calibration curves 
were generated over the range of 1-1000 ng/mL for plasma or 30-60000 ng/g for 
tissue homogenates.  Samples that were diluted 1:10 (v/v) with plasma were 
accurately quantitated allowing for dilution of samples that were > 1000 ng/mL.  The 
accuracy and within- and between-day precisions were within the acceptance criteria 
for bioanalytical assays. 
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Ras-GTP assays from tissue 
Tissue harvested for Ras-GTP assays was snap frozen immediately in liquid nitrogen. 
Before lysis for the assay, the tissue fragments were ground to a fine powder using a 
liquid nitrogen-cooled mortar and pestle. The powdered tissue was lysed in ice-cold 
Mg2+ lysis buffer (25mM Hepes pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 10mM 
MgCl2 and 2% glycerol). The remainder of the Ras-GTP assay was conducted as 
described in chapter I.  
Western blotting from tissue 
Tissue samples from tumours were snap-frozen in liquid nitrogen immediately after 
harvesting. Tissue samples were lysed in SDS lysis buffer with protease and 
phosphatase inhibitors.  
The procedure for western blotting is described in detail in chapter I. The antibodies 
used are listed in table M1.2. Additional antibodies used are listed in Table M2.1 
Antibody Source Dilution 
Kras (F234)  Santa Cruz Biotechnologies 1:1000 
Akt  Cell Signaling 1:1000 
Survivin Cell Signaling 1:1000 
Bip Cell Signaling 1:1000 
p21 Santa Cruz Biotechnologies 1:1000 
Table M2.1 Antibodies for westerns 
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Quantification of proliferation 
 Tumour proliferation was quantified using phospho histone H3 
immunohistochemistry. The number of positive and negative nuclei were enumerated 
in 5 20X fields, and proliferation was presented as a percentage of the total number of 
cells. Proliferation of stromal cells was quantified as a percentage of alpha smooth 
muscle cells staining for Ki67.  
Statistical analysis 
Graphpad prism software was used for statistical analysis. The Log-Rank (Mantel-
Cox) test was used for analysis of survival curves. Proliferation and metastatic burden 
were analyzed using the Mann-Whitney test. Metastatic incidence was calculated by 
the Chi square test. 
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RESULTS 
Detection of tumours by high-resolution ultrasound 
For therapeutic studies, mice harboring the conditional LSL-KrasG12D and LSL-
Trp53R172H alleles are bred to Pdx-1-Cre mice to direct expression of these alleles to 
the pancreas.   LSL-KrasG12D; LSL-Trp53R172H; Pdx-1-Cre (KPC) mice develop 
pancreatic cancer with a 100% penetrance, and have a median survival of 5.6 months 
(28), although with variable latency. High-resolution ultrasound is a non-invasive 
imaging technique that allows the accurate measurement of tumour size to standardize 
enrolment of mice onto therapeutic studies (43, 188).  
Starting at two months of age, mice are examined by palpation to detect pancreatic 
tumours. Palpation is a simple non-invasive method of pre-screening that reduces the 
number of ultrasound scans required. Once a palpable mass is detected, the mice are 
subjected to a pre-screening ultrasound. Mice with tumours <6 mm in mean diameter 
are followed by weekly ultrasound. Mice with pancreatic tumours between 6-9 mm 
mean diameter are suitable for therapeutic intervention. Short-term studies do not 
require follow-up ultrasounds, but mice on survival studies are scanned bi-weekly till 
end-point (Fig 2.1A).  
Ultrasound images give information not only about size, but also about tumour 
location and characteristics. In Fig 2.1B, a pancreatic tumour is seen between a loop 
of intestine and an area of diseased pancreas. Both tumour and diseased pancreas have 
cystic areas.  
  
Fig 2.1 Use of high-resolution ultrasound to image pancreatic tumours The 
schematic represents the method used to identify mice with PDA. Mice are pre-
screened by palpation from the age of two months onwards. Once a palpable mass is 
detected, an initial ultrasound is conducted to confirm the presence of a tumour. Mice 
with detectable tumours of < 6mm mean diameter are screened weekly to follow 
tumour growth. Mice bearing tumours between 6-9 mm are enrolled on study. Short 
term intervention does not involve further ultrasounds. Any animals enrolled onto a 
survival study will receive bi-weekly ultrasounds during the course of treatment (A). 
A sample ultrasound image showing a pancreatic tumour in the abdomen (B). The 
depiction on the right is a representation of the  ultrasound image. The tumour is in 
the centre of the image (pink), with a cyst within the tumour represented in white. To 
the right is an area of diseased pancreas (purple), also with a cyst (white). The blue 
area on the left is a cross-section through the intestine with the lumen visible (B). 
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Farnesylthiosalicylic acid in combination with gemcitabine improves survival of 
tumour-bearing KPC mice 
Since farnesylthiosalicylic acid (FTS) inhibits Ras in vitro and in xenograft models 
(177-179, 186, 189), the efficacy of this molecule as a pancreatic cancer therapy was tested  
in KPC mice. FTS was administered daily at a dosage of 100mg/kg by oral gavage. 
Gemcitabine was administered by intraperitoneal injection twice weekly at 100mg/kg 
(Fig 2.2A). Additionally, bi-weekly ultrasounds were carried out for survival studies 
(Fig 2.2A), but not for short-term intervention (Fig 2.2B).  
The combination of FTS and gemcitabine leads to a significant extension in median 
survival (29 days), compared to vehicle-treated animals (12 days, p=0.0175). 
Gemcitabine monotherapy did not improve survival, with mice surviving a median of 
13 days (p=0.3218). Single-agent FTS also did not have a beneficial effect on median 
survival, with mice living 15 days (p=0.0175) (Fig 2.3, Table 2.1). The combination 
therapy was not significantly different from gemcitabine alone (p= 0.2461). It should 
be noted, however, that there was a nearly 50% increase in survival on the 
combination therapy compared to gemcitabine alone, that therefore merits further 
investigation.  
GROUP COHORT 
SIZE 
MEDIAN 
SURVIVAL 
 IN DAYS
p value  
compared to 
vehicle 
Vehicle 11 12   
Gem 11 13 0.3218 
FTS 11 15 0.8901 
FTS + Gem 16 29 0.0175  
Table 2.1 Analysis of median survival  
 
  
 
Fig 2.2 FTS study structure. Mice on long-term intervention are subject to the 
protocol outlined in (A). Mice are enrolled on study following identification of 
tumours between 6-9 mm mean diameter (Day -1). FTS is dosed at 100mg/kg daily by 
oral gavage. Gemcitabine is dosed by intraperitoneal injection at 100mg/kg twice 
weekly. Tumour growth is followed by twice weekly ultrasounds until endpoint. For 
short-term studies (B), the same enrolment criteria and dosing scheme are followed.  
However, follow-up ultrasounds are not carried out during the course of treatment, 
and mice are euthanized on Day 7 (B).   
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Fig 2.3 FTS in combination with gemcitabine extends survival The cohort treated 
with the combination of FTS and Gemcitabine has a median survival on study of 29 
days, a significant extension over vehicle-treated mice (11 days, p=0.0175). 
Gemcitabine by itself does not extend survival compared to vehicle (13 days, 
p=0.3218). FTS as a single agent does not affect survival (15 days, p=0.8901). 
Although the increase in survival of the combination arm is not statistically significant 
compared to gemcitabine (p=0.2461), it should be noted that the combination results 
in an almost doubling of median survival.  
 
89 
 
90 
 
Tumour kinetics are delayed by combination therapy 
In order to address whether FTS affects tumour growth, ultrasound images were 
quantified. Three-dimensional images were used to generate volumetric 
measurements by outlining the tumours on sequential two-dimensional frames. The 
initial tumour volumes on enrolment were not different between the four treatment 
groups (Fig 2.4A), confirming that results were not biased.  
KPC tumour growth in untreated mice is very rapid, as seen by the traces of 
individual tumours (Fig 2.4B). Gemcitabine overall did not affect tumour kinetics, 
with only responders to treatment showing a slight decrease in growth rates. FTS as a 
single agent had no effect on tumour growth. Tumours in mice that received the 
combination of FTS and gemcitabine grew slower than tumours in any of the other 
three groups (Fig 2.4B).  
FTS does not affect tumour histology 
Previous therapeutic work in KPC mice has shown that tumour histology after 
treatment can provide information on the mechanism of action of the drug (43).  
Despite the increase in survival and the reduction in tumour kinetics, the combination 
therapy did not have any obvious noticeable effects on tumour histology. Tumours at 
end point displayed mixed ductal (Fig 2.5A), sarcomatoid (Fig 2.5B) and solid 
characteristics, with deposition of extracellular matrix and abundant stroma (Fig 
2.5C). FTS also did not prevent the development of liver metastases (Fig 2.5D). An 
analysis of lung metastasis could not be carried out, as lung tissue was harvested for 
pharmacokinetic analysis.  
  
Fig 2.4 Combination treatment decreases tumour growth. Initial tumour volumes 
are equal across the four cohorts, indicating that the effects of treatment are not biased 
(A). Analysis of tumour growth by volumetric ultrasound measurements shows that 
single agent FTS does not affect tumour kinetics compared to vehicle. Gemcitabine as 
a single agent affects tumour growth in a fraction of responders, as expected. The 
combination of FTS and gemcitabine, however, reduces the growth rate of the 
majority of tumours. Each trace represents an individual animal (B).  
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Fig 2.5 FTS does not affect tumour histology FTS-treated tumours exhibit ductal 
(A) and sarcomatoid (B) morphologies. Tumour stromal content did not appear to be 
affected (C). FTS treatment did not completely prevent the formation of liver 
metastases (D).   
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Proliferation is decreased in tumours by combination treatment 
Since tumour growth is affected by combination treatment, proliferation in tumours 
was measured by phospho-histone H3 immunohistochemistry. Combination treatment 
results in a lowered rate of tumour proliferation (1.058% +/- 0.2170), a significant 
decrease compared to vehicle (5.167% +/- 1.834, p=0.0357). FTS monotherapy does 
not alter proliferation with a rate of 4.19% +/- 1.798 (p=0.8571). Gemcitabine by 
itself lowered proliferation slightly, although this was not significantly different 
(2.775% +/- 1.161, p=0.1143) (Fig 2.6A).  
Stromal proliferation was also analyzed by co-immunofluorescence for alpha-smooth 
muscle actin and Ki67. There was no difference in the proliferation of activated 
myofibroblasts in response to treatment. Stromal proliferation in the combination-
treated tumours was 5.17% +/- 1.712, compared to vehicle which was 7.713 +/- 1.711 
(p=0.1143). Neither gemcitabine (7.123 +/- 0.9429, p=0.8857) more FTS (12.44% +/- 
2.4, p=0.0571) as single agents affected proliferation in alpha-smooth muscle actin 
positive cells, although FTS alone appeared to induce a slight increase (Fig 2.6B). 
To determine whether increased apoptosis might be involved in decreasing tumour 
growth, tumours were stained for cleaved caspase 3. There was no change in 
apoptosis in any of the treatment groups, with the tumours overall having a very low 
level of apoptosis (representative images, Fig 2.6C). 
FTS is detectable in plasma and tumour tissue at end-point 
It has been previously reported that pancreatic tumours in the KPC model are poorly 
perfused and display decreased delivery of the chemotherapeutic agent gemcitabine  
  
Fig 2.6 Treatment of KPC tumours with a combination of FTS and gemcitabine 
decreases tumour proliferation. Phosphohistone H3 analysis reveals that 
gemcitabine does not significantly affect proliferation compared to vehicle 
(p=0.1143), and neither does FTS as a single agent (p=0.8571). FTS when combined 
with gemcitabine leads to a significant decrease in proliferation compared to vehicle 
(p=0.0357) and gemcitabine (p=0.0317) (A). Proliferation of stromal fibroblasts is not 
affected in any of the treatment arms (B). Cleaved caspase 3 immunohistochemistry 
reveals that the combination treatment does not induce apoptosis compared to 
gemcitabine (C).  
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Fig 2.7 FTS is successfully delivered to pancreatic tumours. Pharmacokinetic 
analysis of FTS reveals that drug levels in plasma (A) and tissue (B) are variable. FTS 
was detected in all tumour samples processed, at comparable levels to drug found in 
the lungs, which is used as a reference (B).   
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(43). In order to confirm that FTS was delivered to tumours successfully, 
pharmacokinetic analysis was conducted on plasma and tissue samples from treated  
mice. In all mice studied, FTS was detected in plasma as expected (Fig 2.7A). FTS 
was also present in measurable levels in all tumours analysed, although at varying 
levels from tumour to tumour (Fig 2.7B). The same variability in FTS levels was seen 
in lung tissue, which was used as a reference (Fig 2.7B, Table 2.2). The reason for 
this variability is unknown, but FTS levels do not correspond to survival.  
ANIMAL ID Plasma FTS 
(ng/mL) 
Tumour FTS 
(ng/g) 
Lung FTS 
 (ng/g) 
TB139 1692.4 596.1 1128.9 
CR14735 698.9 391.2 1486.2 
CR15276 752.1 322.2 381 
TB1627 1310.1 401.7 712.2 
T2831 1635.2 394.5 799.2 
T862 2413.5 1851.6 31070.7 
T2582 1153.4 459 1306.8 
CR11443 691.2 324.3 954 
T2296 740.1 912 343.8 
TB210 3565.3 2027.4 3078.3 
TB405 1244.5 1811.1 2722.8 
CR16107 935.3 346.8 389.1 
T3943 9653.3 1640.7 3423.3 
CR13730 1466.2 924 549.3 
CR16602 173.4 220.2 279.3 
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TB501 2456.6 373.2 858.6 
Table 2.2 Pharmacokinetic analysis of FTS levels in plasma, tumour and lung 
tissue.    
FTS does not appear to modulate Ras signalling in KPC tumours 
Since FTS is described as an anti-Ras therapy, tumours at end-point were examined 
for Ras activity and signalling to determine whether this was the mechanism for 
decreased tumour growth and proliferation. Western blots were performed on tumours 
from all four treatment groups. There was no difference in levels of total Ras-GTP or 
of active Kras upon treatment with FTS. FTS also did not affect levels of either Kras 
alone or total Ras in tumours. In addition, there was no difference in phospho-Akt in 
treated tumours. FTS did not diminish levels of phospho-ERK in end-point tumours. 
On the contrary, three combination-treated tumours had high levels of phospho-ERK, 
although this was not seen in the FTS alone group (Fig 2.8). Total ERK was used as 
the loading control.  
Immunohistochemistry for phospho-ERK confirmed that this downstream target of 
Ras signalling was not altered. Tumours in all four groups at end point had robust 
phospho-ERK signal in tumour cells (Fig 2.9).  
Further analysis on tumours also showed that FTS treatment did not affect other 
signalling molecules and targets downstream of Ras including phosphorylated S6 
ribosomal protein, p38 MAP kinase and cyclin D1 (Fig 2.10). There was also no 
alteration in levels of both Bip and survivin, although FTS has been shown to down-
regulate both of these proteins (191, 192) (Fig 2.10).  
  
 
Fig 2.8 FTS does not appear to modulate Ras signalling. Analysis of end-point 
samples from long-term intervention studies reveals that FTS does not alter levels of 
active Ras or total Ras compared to vehicle and gemcitabine-treated tumours. In 
addition, there is no inhibitory effect of FTS treatment on levels of phospho-ERK or 
phospho-Akt. Total ERK is used as a loading control.  
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Fig 2.9 Phospho-ERK levels in vivo are not altered by FTS treatment. 
Immunohistochemical analysis of phospho-ERK at end-point reveals that FTS 
treatment, either by itself or in combination with gemcitabine, does not lower levels 
of phospho-ERK in comparison with vehicle or gemcitabine. (Scale bar = 200µm). 
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Fig 2.10 FTS does not affect signalling at end-point. Further examination of 
tumours at end point reveals that there is no decrease in phosphorylation of S6 
ribosomal protein or p38 MAP kinase, and no alteration in levels of Cyclin D1, cyclin 
B, survivin and Bip.  
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There is no modulation of Ras signalling by short-term intervention  
End-point tumours, which have been subjected to longer periods of FTS exposure, 
might lack alterations to Ras signalling due to escape mechanisms or feedback loops. 
In order to determine whether Ras signalling is indeed affected in pancreatic tumours, 
a short-term analysis was performed by treating KPC tumour-bearing mice with FTS  
for 7 days. The tumours were then subjected to a similar analysis as those at end-
point.  
At this short timepoint, there was no modulation of either Ras levels, or signalling 
modules downstream of Ras including phosphorylation of ERK, Akt, S6, p38 and 
Rsk. There was also no difference in levels of cyclin D1, survivin and Bip (Fig 2.11), 
confirming that FTS in the KPC model of pancreatic cancer does not affect Ras 
signalling, or previous known targets of the inhibitor. These results were also 
recapitulated in patient-specific xenografts, which have been previously described (31).   
Tissue samples of patient-specific xenografts treated with FTS were obtained and 
were analysed for effects on Ras signalling. There were no changes in Ras-GTP, 
phospho-ERK or phospho-Akt (Fig 2.12).  
FTS affects liver metastatic burden 
In order to examine the effect of FTS treatment on metastasis, the burden of liver 
metastasis was quantified by counting the number of metastatic lesions in the livers of 
mice in the different treatment groups. The combination of FTS and gemcitabine led 
to a significant decrease in the number of metastases per mouse (0.454 +/- 0.5222) 
compared to vehicle-treated mice (5.875 +/- 5.693, p=0.0045). Neither gemcitabine 
(10.67 +/- 20.35, p=0.6978) nor FTS alone (4.909 +/- 10.79, p=0.1068) had this effect  
  
Fig 2.11 Short-term analysis of FTS treatment on signalling in tumours.  
Treatment of tumours for 7 days confirms that FTS does not inhibit Ras signaling in 
pancreatic tumours. There are no changes in levels of Ras, or in phosphorylation of 
molecules downstream of Ras such as ERK, Akt, S6, Rsk and p38 MAP kinase. FTS 
treatment also does not affect the expression of cyclin D1, survivin or Bip.  
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Fig 2.12 FTS does not alter Ras signalling in patient-specific xenograft tumours. 
There are no changes in ras activity or levels or phosphorylation of ERK or Akt in 
response to FTS, either as a single agent or in combination with gemcitabine, in 
patient-specific xenografts. 
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Fig 2.13 FTS combination treatment decreases the burden of liver metastasis. 
Although treatment with FTS does not prevent liver metastasis, FTS in combination 
with gemcitabine significantly decreases the burden of liver metastases compared to 
vehicle-treated animals (p=0.0045). Gemcitabine (p=0.6978) and FTS (p=0.1068) as 
single agents do not inhibit liver metastasic burden (A). There was no significant 
difference between any of the groups in the size of metastases to the liver (B). 
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(Fig 2.13A). There was no significant difference between any of the treatment arms 
with regards to tumour size (Fig 2.13B).  
FTS, whether alone or in combination with gemcitabine, significantly decreased the 
incidence of liver metastasis with only 45.45% of mice developing metastases to the 
liver compared to 87.5% of vehicle-treated mice (Table 2.3, p=0.0141). Gemcitabine  
alone decreased the incidence of metastasis to 67.67%, although this was not 
statistically significant (p=0.3619).  
Genotype Number 
of mice 
Mice with 
liver 
metastases 
Incidence 
of liver 
metastasis 
Vehicle 8 7 87.5% 
Gemcitabine 9 6 67.67% 
FTS 11 5 45.45% 
FTS + Gem 11 5 45.45% 
Table 2.3 Incidence of liver metastasis 
FTS does not decrease phospho-ERK in liver metastases 
Pharmacokinetic analysis of liver tissue revealed that the liver accumulated 15-30 
times more FTS than tumour tissue (Fig 2.14A). Due to this large difference, liver 
metastases were examined to determine whether phospho-ERK was decreased in 
response to FTS. Immunohistochemistry revealed that there was no difference in 
phospho-ERK in liver metastasis after FTS treatment (Fig 2.14B), further 
corroborating that the response of pancreatic tumours to FTS is not a result of altered 
Ras signalling.  
  
 
 
Fig 2.14 Phospho-ERK levels in liver metastases are not affected by FTS 
treatment. Pharmacokinetic analysis of the liver reveals that liver tissue accumulates 
15-30 times more FTS than pancreatic tumour tissue (A). Despite this increase in drug 
levels, phospho-ERK is not changed in liver metastases from FTS-treated mice 
compared to vehicle-treated mice (B).  
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DISCUSSION 
FTS is a derivative of farnesylated  rigid carboxylic acids. It mimics the farnesylated 
moiety of Ras by binding to adaptor proteins such as galectin in the plasma 
membrane. In this manner, FTS prevents active Ras from anchoring to the membrane, 
leading to its degradation and the inhibition of downstream signalling (177-179, 189). In 
vitro experiments demonstrated that FTS selectively inhibited Ras-dependent cell 
growth, transformation and survival (178, 180, 185, 191, 193, 194). Additionally, FTS inhibited 
growth in xenograft models of neurofibromatosis, breast cancer, melanoma, Merkel 
cell carcinoma and pancreatic cancer (186, 195-198).  
FTS was tested in the KPC mouse model of pancreatic cancer to evaluate its efficacy 
as a therapeutic agent in this disease. FTS as a monotherapy did not have an effect on 
survival, but in combination with gemcitabine led to a substantial increase in median 
survival. This effect was associated with delayed tumour kinetics and decreased 
proliferation in tumours. In addition, combination therapy decreased the burden of 
liver metastasis, and treatment with FTS decreased the incidence of liver metastasis 
both as single agent and combination treatment. Despite these effects, FTS in this 
mouse model did not appear to decrease ras activity or modulate ras signalling in 
either end-point analyses or short-term intervention studies in primary tumours and 
liver metastases. 
A simple explanation for the effect of FTS in the KPC model of pancreatic cancer 
may be the augmentation of gemcitabine delivery, thereby improving survival. This 
phenomenon has been previously reported in this model in combination therapy (43).  
Although FTS is reported to be a ras inhibitor, evidence from the literature also 
suggests that it has other molecular targets. In MCF-7 cells, for instance, FTS inhibits 
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mTOR with minimal effects on MAPkinase signalling (199), a result that is 
recapitulated in MEFs where FTS inhibits S6kinase activation by mTOR and 
decreases mTOR levels (200). The effects of FTS on mTOR signalling appear to be due 
to the dissociation of the mTOR-raptor complex (201). FTS may also be able to 
independently influence p53 function, although this requires further investigation (202).  
In addition, as it mimics farnesylated moieties, FTS may have the potential to inhibit 
other farnesylated proteins which include protein tyrosine phosphatases, inositol 
polyphosphate phosphatases and phospholipase A2 among others (203-205). Other 
proteins which have carboxyl terminal CAAX that might make them candidates for 
farnesylation include bone morphogenetic proteins, transforming growth factor-beta 
precursors and serine-threonine kinase 11, which have potential roles in regulation of 
growth (163). Alternatively, the feedback loops that regulate signalling downstream of 
ras such as the MAP kinase phosphatases and dual-specificity phosphatases may be 
altered, to compensate for decreased ras activation. 
The galectins are a group of carbohydrate binding proteins that exhibit diverse 
biological activities. They have a number of extracellular and intracellular functions. 
They are capable of cross-linking cell surface glycoproteins and transducing 
signalling events across the plasma membrane. More importantly, and perhaps more 
relevant to FTS, are their intracellular functions which include regulation of pre-
mRNA splicing, cell growth, apoptosis and cell cycle progression. These functions 
involve protein-protein interactions, although the binding sites in galectin have yet to 
be identified (206-209). It is conceivable, however, that the binding of FTS to galectins 
may interfere with their intracellular functions by preventing such protein-protein 
interactions, and may be responsible for the effects that FTS engenders in pancreatic 
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tumours. Alternatively, galectins might be upregulated in tumours in response to FTS 
treatment, to compensate for the competitive inhibition of active ras proteins. Indeed, 
galectin-3 is known to serve as a scaffold that augments ras activation, and a 
dominant-negative galectin-3 abrogates signalling down the MAP kinase cascade (210). 
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CONCLUSIONS/FUTURE DIRECTIONS 
In summary, FTS treatment in combination with gemcitabine extends survival in 
tumour-bearing mice, with a corresponding decrease in tumour kinetics, proliferation 
and liver metastasis. The mechanism of action of FTS in pancreatic cancer does not 
appear to be clear-cut as there is no change in levels of ras protein or ras activity, as 
would be expected if ras was unable to localize to the membrane in response to 
therapy. Furthermore, there is no alteration in signalling modules downstream of ras, 
further corroborating the lack of ras modulation and indicating that FTS may 
influence survival in the KPC model of pancreatic cancer through a mechanism other 
than ras inhibition.   
Compensation 
In response to treatment, tumours are capable of altering gene expression patterns to 
compensate for inhibition by therapeutic agents. The proteins in the MAP kinase 
family, including ERK, SAPK and Jnk, are regulated by a number of phosphatases 
such as the MAP kinase phosphatases and dual specificity phosphatases (reviewed in 211). 
It is possible that these phosphatases are altered upon treatment with FTS as an early 
response to changes in signalling downstream of ras. Tumour samples and cell lines 
treated with FTS must be examined for changes in these proteins, which might 
indicate a response to therapy and restoration of signalling. An alternative method of 
compensation would be the upregulation of the galectins. Overexpression of galectins 
would overcome competitive inhibition by FTS, and ras would be able to localize to 
the membrane and activate downstream signalling.  
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FTS and proliferation 
Since FTS in combination with gemcitabine slows tumour kinetics, and proliferation 
is decreased without a change in apoptosis, the mechanism by which FTS affects 
proliferation should be examined. This can be performed in vitro using tumour cell 
lines. Cell cycle analyses should be conducted to determine whether FTS treatment 
results in alteration of cell cycle profiles. In addition, various cell cycle regulators 
should be compared post treatment with FTS. These experiments will also permit the 
investigation of differential effects on cells of gemcitabine and FTS alone and in 
combination. 
FTS and gemcitabine 
Although pharmacokinetics demonstrates that FTS can be measured in tumour tissue, 
it has not yet been determined whether the intracellular drug concentrations are 
sufficient to inhibit oncogenic ras. Most in vitro studies of FTS biochemistry have 
been conducted using micromolar concentrations of drug in cell culture systems. FTS 
in tumour tissue does not accumulate to such high concentrations, and the presence of 
desmoplasia and other cell types may interfere with the ability of the drug to reach the 
target cell population. The effect of lower concentrations of FTS on ras signalling 
may be determined in cell culture to determine whether the lack of ras modulation in 
pancreatic tumours is simply due to insufficient drug concentrations.  
The survival benefit imparted by FTS in combination with gemcitabine may be due to 
improved delivery of the chemotherapeutic agent to pancreatic tumours. This is a 
phenomenon that has been previously reported in this model (43). The levels of 
gemcitabine should be determined in FTS-treated tumours to determine whether 
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increased gemcitabine levels may account for the decreased proliferation seen in 
tumours.  
Other targets of FTS 
As has been previously discussed, FTS is thought to have other targets than ras, 
including p53 and mTOR (199-202). Tumour samples must be analyzed to determine 
whether FTS has additional targets in cells. Gene expression profiles have been 
previously used to generate signatures of treated cells which are indicative of specific 
responses to therapy (212). Such expression profiles carried out in FTS-treated 
pancreatic tumours may give an indication of targets that are being affected. Tumour 
cells must be isolated from tumours by laser capture microdissection in order to 
eliminate contamination from the microenvironment. A similarly useful approach 
would be a proteomic or phospho-proteomic analysis to elucidate alterations in 
protein profiles or signalling modules.  
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APPENDIX 1 
 
No. Protein name Fold change 
1 6Ckine -1.26 
2 ALK-1 -1.10 
3 Amphiregulin 1.01 
4 Axl 2.15 
5 BLC 1.04 
6 Cardiotrophin-1 -1.06 
7 CD27 1.68 
8 CD27 L 1.02 
9 CD30 1.23 
10 CD30L -1.06 
11 CD36/SR-B3 1.19 
12 CTLA-4 -1.30 
13 CXCL16 1.51 
14 Decorin 1.97 
15 Dkk-1 1.78 
16 E-Cadherin -1.29 
17 EGF -1.19 
18 Eotaxin -1.13 
19 Eotaxin-2 -1.16 
20 Epigen -1.32 
21 E-Selectin -1.14 
22 Fas Ligand -1.76 
23 Fcg RIIB -1.10 
24 Flt-3 Ligand -1.33 
25 Fractalkine 1.09 
26 Galectin-1 1.13 
27 Gas6 -1.11 
28 GCSF -1.59 
29 GITR -1.23 
30 GITR ligand 1.07 
31 Granzyme B 1.16 
32 HAI-1 1.04 
33 HGF -1.01 
34 IFN gamma -1.32 
35 IGFBP-5 1.12 
36 IGFBP-6 -1.32 
37 IGF-II -1.05 
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38 IL-1 alpha 1.12 
39 IL-1 beta 1.67 
40 IL-1ra 1.12 
41 IL-2 1.26 
42 IL-2 R alpha 1.21 
43 IL-3 -1.23 
44 IL-4 -1.20 
45 IL-5 -1.17 
46 IL-6 -4.08 
47 IL-9 -1.44 
48 IL-10 -2.21 
49 IL-11 -1.13 
50 IL-12 p40 3.76 
51 IL-12 p70 -1.52 
52 IL-13 -1.29 
53 IL-15 1.59 
54 IL-17 1.11 
55 IL-17B R -1.04 
56 IL-17E 1.53 
57 IL-17F 1.41 
58 IL-20 1.43 
59 IL-21 1.13 
60 I-TAC -1.55 
61 JAM-A -1.21 
62 KC -1.68 
63 Leptin -1.03 
64 Leptin R -1.36 
65 L-Selectin -1.32 
66 Lungkine 1.26 
67 Mad CAM-1 1.03 
68 MCP-1 -1.07 
69 MDC -1.09 
70 MFG-E8 -1.08 
71 MIG 1.08 
72 MIP-1 alpha -1.69 
73 MIP-1 gamma 1.08 
74 MIP2 -1.90 
75 MIP-3 alpha -1.04 
76 MIP-3 beta -1.15 
77 MMP-2 -1.20 
78 Osteopontin -1.16 
79 Osteoprotegerin 1.86 
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80 Prolactin 2.44 
81 SCF -1.44 
82 sTNF RI 1.88 
83 sTNF RII 1.24 
84 TACI 1.17 
85 TARC 1.13 
86 TNF alpha -1.20 
87 TPO -1.16 
88 TRANCE -1.51 
89 TROY -1.12 
90 TWEAK R 1.01 
91 VCAM-1 1.14 
92 VEGF 1.08 
93 VEGF R1 -1.46 
94 VEGF R3 1.24 
95 VEGF-D 1.12 
 
Appendix 1: Cytokine array analysis from tumours 
Comparison of cytokine profiles between tumours from KPC;B+/+ and KPC;B-/- 
mice using an antibody-based array. The fold change listed is relative to KPC;B+/+ 
tissue. 
 
